Podcasts about eliza hall institute

In this episode of the Scope of Things, host Deborah Borfitz brings you the latest news on AI-recommended precision dosing, organoid drug testing aiding treatment selection for bowel cancer, an AI tool for stratifying lung cancer patients, using HIV drugs to treat Alzheimer's disease, and the potential value of magic mushrooms to remedy the mood symptoms of Parkinson's. Blythe Adamson, international head of outcomes research and evidence generation at Flatiron Health, also joins in to discuss groundbreaking work harmonizing patient-level real-world data across four countries to enable multinational oncology research.  News Roundup CURATE.AI platform Article in Clinical Research News Study in npj Precision Oncology   FORECAST-2 clinical trial News on the Walter and Eliza Hall Institute website AI tool for sorting cancer patients Study in Nature Communications  HIV drugs for Alzheimer's protection Study in Alzheimer's & Dementia “Magic mushrooms” for Parkinson's disease Study in Neuropsychopharmacology Guest Blythe Adamson, Ph.D., international head of outcomes research and evidence generation at Flatiron Health  Flatiron Health enabling multinational oncology researh – article in Bio-IT World  Subscribe to the podcast on Apple Podcasts and leave a review to support the show. Join us at Scope Europe on October 14-15 in Barcelona - use code SOT10 for an additional 10% discount. GUEST BIO Blythe Adamson, PhD, MPH, Head of Outcomes Research and Evidence Generation, International at Flatiron Health & Founder of Infectious Economics Dr. Blythe Adamson is the head of international outcomes research and evidence generation at Flatiron Health.   As a visionary senior leader at Flatiron Health, her team pioneered deep learning language models for extraction of clinical details from EHR documents, breaking the limits of what was possible for humans to do alone. Learning from the experience of millions of patients with cancer, they generate evidence of treatment effectiveness and value used by governments around the world. Dr. Adamson co-invented a patented clinical decision-support tool, enabled by machine learning, that is used by cancer clinics to benefit patients.   She holds degrees in microbiology, epidemiology, and pharmaceutical economics with a focus on infectious disease prevention. Dr. Adamson has held roles at the Bill and Melinda Gates Foundation Institute for Disease Modeling, the NIAID HIV Vaccine Trials Network, and Flatiron Health. The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

A Gluten Free PodcastEpisode 176On today's episode I chat with Associate Professor Dr Bob Anderson — a world-renowned gastroenterologist, immunologist and trailblazer in coeliac disease research. From his foundational work at the Walter and Eliza Hall Institute (WEHI) to creating Nexvax2, leading Novoviah Pharmaceuticals, and becoming President of the International Society for the Study of Coeliac Disease (ISSCD), Bob has shaped the coeliac research landscape as we know it.We discuss how his career began, what he's most excited about in current research, and what's ahead for coeliac disease globally — including a look at ICDS 2026 in Melbourne.What We Cover

PRESS REVIEW – Friday, March 14: We look at reactions from the European papers as Vladimir Putin says he's open to a ceasefire but says the conditions need to be reworked. For the press, the Russian President is dictating his terms. Also, the British Prime Minister Keir Starmer announces sweeping changes to the National Health Service. And, a major breakthrough in research on Parkinson's disease. Finally, Donatella Versace will step down from the Versace fashion house after thirty years.  Reactions from the European press over a proposed peace plan between Ukraine and Russia. President Vladimir Putin says he supports a US-brokered peace plan, in theory, without offering any guarantees. The feeling in the press is that he's very much in control. French paper Liberation says a "cease-what" on its front page sarcastically. In its editorial, Libe notes that Putin was seen in military fatigues visiting Kursk earlier this week. He also appeared to make US envoy Steven Witkoff wait while he met with Belarussian President Alexander Lukashenko. Putin continues to play his "deadly game of poker against the West," the daily says. For Le Figaro, it's the "yes, but" response of Putin that complicates Donald Trump's hopes of brokering a ceasefire. The paper also picking up on Putin's behaviour in Kursk, as one who believes he is close to victory. Le Soir, the Belgian paper notes Putin plays the ambiguity card and keeps the pressure on as he dictates his terms while der Taggespiegel sees it as an outright rejection by Putin of the ceasefire deal. Syrian cartoonist Fahd Bahady echoes those sentiments – portraying a Donald Trump dove of peace pooping all over Zelensky. The Kyiv Independent chooses to focus on Volodymyr Zelensky's evening address on Thursday in which he said Putin is afraid to admit to Donald Trump that he doesn't want a ceasefire because he wants to keep killing Ukrainians. He also added that Moscow is demanding for impossible conditions to postpone ceasefire talks for as long as possible.The Italian daily Corriere della Sera looks in detail at what Putin wants in exchange for a ceasefire: notably that Ukraine gives us four regions occupied by Russian soldiers, Luhansk, Donetsk, Zaporizhzhia and Kherson as well as provinces still in Ukraine's hands. For the Italian daily, in Putin's eyes, Europe should be relegated to a marginal role and his neo-imperial, 19th century vision corresponds to that of Trump.British Prime Minister Keir Starmer has made sweeping changes to the National Health Service, which is dominating front pages there. Starmer announced a restructuring plan to abolish the NHS England body to cut red tape and bring management of the health service under the health ministry. The move will lead to several thousand jobs lost but will save the government hundreds of millions of pounds a year. For the Daily Telegraph, Starmer's taking on an £800-million gamble. The Guardian notes that the NHS England is financed by the government but runs independently. It was established just over a decade ago by the conservatives in what Wes Streeting, current health minister calls a disastrous reorganisation that needed to be scrapped. The tabloid Daily Mail rejoices in the decision, saying patients will be put before bureaucracy and care will be improved. The government has said the job losses will be because of the duplications of jobs within both the NHS and Health ministry.Staying on the topic of health: Australian scientists are hailing what they hope could be a huge breakthrough in the fight against Parkinson's disease. Twenty years ago, PINK 1 was identified as the protein linked to Parkinson's disease, but for two decades, no one knew what the protein looked like or how it switched on with the onset of the disease. A hallmark of Parkinson's disease is the death of brain cells. Researchers at the Walter and Eliza Hall Institute of Medical Research based in Victoria, Australia have determined how the mutation switches on. They can use this discovery to find a way to switch it off and notably slow down the progression of Parkinson's, which is the fastest growing neurodegenerative condition in the world. Finally: Donatella Versace, sister of Gianni Versace is stepping down as chief creative officer of her family fashion house after nearly 30 years. The Times of London reports that she stepped in to take over the company after her brother was murdered in 1997. She will stay on as chief brand ambassador. Dario Vitale, former image director of Miu Miu is the new designer. Donatella Versace oversaw a pivotal era in fashion and iconic dresses like Jennifer Lopez's barely-there jungle dress in 2000 that was so researched it actually launched Google's "image search" function! Her departure also coincides with an end to an era in fashion – high octane, glossy and molto sexy, the Times says.

Dr Alexander Perl from Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Richard M Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, Prof Andrew H Wei from Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, and moderator Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center in New York, New York, discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory acute myeloid leukemia.

Dr Alexander Perl from Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Richard M Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, Prof Andrew H Wei from Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, and moderator Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center in New York, New York, discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory acute myeloid leukemia. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHAML24).

SummaryIn this week's episode of The Startup Retro, hosts Gemma Clancy and Will Richards explore three exciting new funds and initiatives in the Australian startup ecosystem, including the launch of the $66 million 66ten fund by the Walter and Eliza Hall Institute, and Main Sequence's new Atmosphere program. They also cover the latest venture from SEEK co-founder Paul Bassett, Amplify, and discuss AustralianSuper's significant $1.1 billion write-off in their Pluralsight investment. The hosts highlight standout startups, including WhyHive, a data analysis tool, and Cropify, an AI-powered grain grading AgTech company. The episode also features an interview with Gav Parry on the launch of the Centre for Arts, Sports and Technology (CAST), and concludes with KaaS recommendations on essential startup content and a special announcement about a new co-host joining next week.Time Stamps00:00 Introduction and Welcome00:28 New Fund Launches and Initiatives06:12 Paul Bassett's Amplify09:45 AustralianSuper's Pluralsight Write-off12:40 Weekly Startup Raises20:30 Interview with Gav Parry on CAST28:00 KaaS Recommendations30:45 Special Co-Host Announcement31:00 OutroHeadlinesThree New Funds and Initiatives66ten Fund: WEHI's $66M fund to back biomedical innovation.Seedlab Australia: Secures an additional $7M from Woolworths to support food, drink, and sustainable products.Main Sequence's Atmosphere: New program to transform cutting-edge research into venture-scale businesses.Paul Bassett Launches AmplifyAmplify aims to improve trust in democracy through events, online conversations, and sharing of evidence.AustralianSuper Write-OffAustralianSuper writes off $1.1B in their Pluralsight investment, which had acquired A Cloud Guru in 2021.Startup RaisesWhyHive: A $600K raise led by Skalata Ventures, making data analysis user-friendly.Cropify: A $2M seed round for AI-powered precision grain grading, led by Mandalay Venture Partners.KaaS - Knowledge as a ServiceGemma's Pick: Crucible Moments (Season 2) by Sequoia Capital, featuring founders of ServiceNow, YouTube, DoorDash, and more.Will's Pick: Blog on common VC scams - OpenVC.Special AnnouncementCheryl Mack from Aussie Angels & The First Cheque podcast will join as a co-host next week while Gemma enjoys a vacation in Italy.  Send feedback to the hostsGemma on LinkedInWill on LinkedInSponsorsThanks to our sponsors for helping to make this episode of The Startup Retro possible.RipplingAre you a founder overwhelmed by HR, payroll, onboarding, and IT tasks? Simplify with Rippling: an all-in-one platform for your global workforce.Get 3 Months Free TeamifiedBuild a top-notch team fast with Teamified. Teamified offers fractional CTOs, contractors, and remote team members from the Philippines, India, or Sri Lanka. Cut hiring times by 50%.Get started The Day One NetworkThe Startup Retro is part of Day One, the podcast network dedicated to founders, operators & investors.For broader updates on the Day One network, including news about other shows and network-wide updates, sign up for the Day One Newsletter. We are dedicated to creating content that helps Australian founders succeed. https://dayone.fm/newsletterSponsor the showWant to become a sponsor? Send us an email.Follow Day One on the socialsTwitterLinkedIn

CIRO and CERAHost: Dr Shane, 1st guest: Prof Doug Hilton CEO CSIRO is a molecular and cellular biologist and previously Director of the Walter and Eliza Hall Institute of Medical Research (WEHI). At WEHI, his medical research focussed on understanding how blood cells communicate and using this knowledge to improve disease treatments. He and his team held more than 20 patents and translated their research through collaboration with venture capitalists and the biopharmaceutical industry. Through an honorary appointment in the Zoology Department at University of Melbourne, he also studies a family of tiny day-flying moths involved in the pollination of Australian plants.2nd guest: Prof Professor Peter van Wijngaarden CERA. An ophthalmologist and medical scientist with research interests in diabetic retinopathy, Alzheimer's disease and retinal imaging biomarker discovery. He has research experience in retinal vascular biology and central nervous system regeneration.Program page: Einstein-A-Go-GoFacebook page: Einstein-A-Go-GoX: Einstein-A-Go-Go

What a treat to have Gus Nossal on the show this week. He joined us on the phone from his home at the last minute. What a trooper. For the uninitiated, Gus is an Australian legend who has been bestowed with many titles and was on the telly all the time back in the day as scientific public intellectual. Gus says that public communication is vital. He was born and raised in Vienna during the 1930s before his family came to Australia on a long boat voyage which was very exciting for young Gus. He always wanted to be a doctor and studied medicine, landing in theoretical virology. His PhD supervisor was Frank Macfarlane Burnet, then he went off to Stanford during a very exciting time in medical science. Gus says he spent hours and hours a day at the microscope. In 1962 he returned to Australia and became the Director of the Walter and Eliza Hall Institute of Medical Research. Gus' big interest was in immunological tolerance and its impacts on the fields of transplants and auto-immune diseases. We'll leave the rest of the story to Gus who recently celebrated his 93rd birthday. Thank-you very much for the chat, Gus, and for all you have done for global health.  

Hello and welcome to Episode 211 of the People Powered Business Podcast! In today's episode I am joined by Mel Rosenthal, professional coach for founders, leaders and teams.Mel is a Professional Certified Coach, accredited by the International Coaching Federation and an Australian Institute of Company Directors graduate (GAICD). She holds a Bachelor of Commerce (First Class Honours) from the University of Western Australia and an MBA from the Kellogg School of Management at Northwestern University. Mel works with Founders and Leaders to drive growth for companies and the people in them. She has been trusted by the leadership of companies including Who Gives A Crap, Minor Figures, Keep Cup, StartUp Victoria, QBE, Tyro, Champion Life, Thoughtworks, The Australian Centre for Social Innovation, Inventium, Advisian, Peter MacCallum Cancer Centre, Walter and Eliza Hall Institute of Medical Research, Swinburne University, Alinta Energy, ME Bank, Visy and Medtronic.Mel is also the creator of 52 Conversations – a card game to create conversations that matter – and that's what our conversation focused on today. Mel shares some stunning statistics that reflect the real costs and risks of not having important conversations with our teams, and shares her insights into how leaders can have more effective and impactful conversations.To leave more about the 52 Conversations Card Game, simply head to this site:https://www.52conversations.com/To learn more about Mel, the work she does and how you can connect with her, head to this website:https://melissajrosenthal.com/Or you can connect on LinkedIn here:https://www.linkedin.com/in/rosenthalmelissa/An InvitationWould you like to connect with other like-minded business owners, leaders and managers experiencing similar situations with their team? Join the discussion inside our free Facebook Group – HR Support for Australian -Businesses. https://www.facebook.com/groups/hrsupportaustralia

In this episode, Josh interviews the man who helped make this grand adventure possible, his mentor, Professor Elgene Lim of the Kinghorn Cancer Centre in Sydney. Professor Lim is a medical oncologist specialising in breast cancer research. He has previously worked at the Walter and Eliza Hall Institute, completing his PhD under the mentorship of Dr Geoffrey Lindeman and Dr Jane Visvader with research focussed on identifying culprit cells in BRCA1 mutant gene carriers. He subsequently worked with Dr Eric Winer and Dr Myles Brown at the Dana-Farber Cancer Institute and Harvard Medical School. As if this was not enough, Elgene is proud of his volunteer work with asylum seekers and his work with the Asha Kiran Hospital in Orissa, India, in a program of expertise transfer and partnership with local doctors. The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.The Kinghorn Cancer Centre: https://tkcc.org.au/Dana Farber Cancer Institute: https://www.dana-farber.org/For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow. Hosted on Acast. See acast.com/privacy for more information.

A Gluten Free Podcast Episode 104My guests on this week's episode are Associate Professor & gastroenterologist,  Jason Tye-Din & Health Advocacy Officer at Coeliac Australia, Penny Desllsperger. We'll talk about the suitability of oats for Australians with coeliac disease, the studies Professor Tye-Din has worked on & how Australians with coeliac disease can trial oats with their health professionals. What we'll cover:* Professor Tye-Din's work & association to Coeliac Australia * Why oats can't be deemed gluten free within Australia * Professor Tye-Din's study researching the reaction the protein avenin within oats has in people with coeliac disease * How Australians can trial oats as part of their gluten free diet * Professor Tye-Din's current & future research Links Associate Professor Jason Tye-Din's Current Coeliac Disease Studies at WEHI (The Walter and Eliza Hall Institute of Medical Research) in Melbourne Coeliac Australia's FAQ on Oats Join A Gluten Free Podcast Facebook GroupGingerbread Folk Gluten Free Selection Use discount code GFFAM1 to save 10% off your order at checkout!Get in touchYou can find me on Instagram @a.gffamily or send an email to aglutenfreefamily@gmail.com 

This week the team are in the studio, with a focus on Immunology (in promotion of the upcoming ‘Day of Immunology') and an exciting work on an oral treatment for Diabetes.Dr Shane is joined in the studio this week by EAGG colleague Dr Ailie and Dr Caleb Dawson.Dr Holly Anderton Senior Postdoctoral Fellow from Walter and Eliza Hall Institute of Medical Research, discusses the complexity of the skin microenvironment and skin immunology.Dr Claire Gordon Senior Research Fellow in the Department of Microbiology and Immunology, Infectious Diseases Physician at Austin Health, Clinical Lead at North-eastern Public Health Unit and Director of the Australian Donation and Transplantation Biobank, explains the importance and sophisticated nature of the immune system, T Cell research in humans and organ donation for research.Professor Charlotte Conn a Biophysical Chemist from RMIT University, joins the team to discuss a new oral capsule treatment delivery system which is being developed for Diabetes right here in Australia.The team finish with some science news, including recent findings regarding a common Fungi which breaks down plastics in 140 days.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a conversation about small cell lung cancer and previews the upcoming IASLC 2023 Hot Topic Meeting: Small Cell Lung Cancer in April which is focused on both preclinical and clinical advances in small cell lung cancer research. Joining the conversation are Alvaro Quintanal-Villalonga, PhD., from the Rudin Lab at Memorial Sloan Kettering Cancer Center in New York, and Kate Sutherland, PhD., from the Walter and Eliza Hall Institute of Medical Research in Australia.

Drew Berry is a biomedical animator who creates beautiful, accurate visualisations of the dramatic cellular and molecular action that is going on inside our bodies. Beginning his career as a cell biologist, his raw materials are technical reports, research data and models from scientific journals. As an artist he works as a translator, from abstract and complicated scientific concepts into vivid and meaningful visual journeys. Since 1995 he has been a biomedical animator at the Walter and Eliza Hall Institute of Medical Research, Australia. His animations have exhibited at venues such as the Guggenheim Museum, Museum of Modern Art, the Royal Institute of Great Britain and the University of Geneva. In 2010 he received a MacArthur Fellowship “Genius Grant". Ted Talk - https://www.youtube.com/watch?v=WFCvkkDSfIU  https://www.drewberry.com/about  Bjork - Hollow - https://www.youtube.com/watch?v=Yn8AC8z2adU  Quantum Biology - https://www.youtube.com/watch?v=zlkF2vxzUsw  DONATE and help the channel grow - https://donorbox.org/help-me-buy-stuff  PRE-ORDER MY GAMESTOP BOOK - https://wen-moon.com  Buy Brexit: The Establishment Civil War - https://amzn.to/39XXVjq    You can listen to the show on Spotify, Apple, and all major platforms - https://chatterpodcast.podbean.com/  Watch Us On Odysee.com - https://odysee.com/$/invite/@TheJist:4    Buy Brexit: The Establishment Civil War - https://amzn.to/39XXVjq  Join My Mailing List - https://www.getrevue.co/profile/thejist  Follow Me On Twitter - https://twitter.com/Give_Me_TheJist  Website - https://thejist.co.uk/    Music from Just Jim – https://soundcloud.com/justjim  Extract Labs CBD - https://extract-labs.pxf.io/n10JMa  Canva Premium Graphics - https://partner.canva.com/b3A9X6 

Zahrah Azman, Perinatal PhD Student at The Ritchie Centre, Hudson Institute of Medical Research, talks about her research on foetal growth restriction (FGR), which is a common pregnancy complication affecting up to 10% of pregnancies in Australia and is defined as the failure of a baby to reach its biological growth potential; Professor Patrick Humbert, Director of the La Trobe Institute for Molecular Science (LIMS), and Dr Jens Hauslage from the German Aerospace Centre, talk about recent experiments they conducted 250km above the Earth on a tiny animal, the Trichoplax, whose ancient biological mechanisms could be used to develop therapeutic or preventative measures for human cancer; and Stefanie Bader, a PhD Candidate at the Pellegrini Laboratory (The Walter and Eliza Hall Institute of Medical Research) explains her research into better understanding how SARS-CoV-2 is causing severe disease and death, and why the immune system is sometimes ‘overreacting' to an infection, leading to a more severe illness. With presenters Dr Shane and Dr Laura.Program page: Einstein-A-Go-GoFacebook page: Einstein-A-Go-GoTwitter: Einstein-A-Go-Go

From chemotherapy to immunotherapy and targeted drug delivery, what's next for breast cancer treatment? In this episode, Jessica is joined by cancer research expert Associate Professor Pieter Eichhorn, who is co-leading an Australian Government subsidised drug delivery project that aims to change the behaviours of proteins found in breast cancer. Together, they discuss what conventional treatments exist and where they're going, Associate Professor Eichhorn's exciting new drug treatment, and what he believes needs to change to drastically reduce the rates of breast cancer going into the future.Associate Professor Eichhorn's research project is supported by the Curtin Health Innovation Research Institute and the National Drug Discovery Centre at the Walter and Eliza Hall Institute.How breast cancer develops [01:15]Predicting future rates of breast cancer [04:26]Progress in conventional treatments [07:56]What's unique about the drug delivery project? [13:27]Associate Professor Eichhorn's research journey [17:34]Reducing rates of cancer through tumour sequencing [19:45] Content note: This episode predominantly covers the experiences of women who are cisgender. Cisgender women are those women whose sense of their gender matches the sex they were assigned at birth and who are the population group at greatest risk of contracting breast cancer.Learn moreWEHI: National Drug Discovery Centre announces new projectsNational Breast Cancer Foundation websiteBreast Cancer Now websiteConnect with our guestPieter Eichhorn is the Dean of Research Infrastructure at Curtin University, and an Associate Professor at the world-renowned Curtin Health Innovation Research Institute.He has devoted his career to developing targeted treatments for breast cancer and melanoma patients. Prior to Curtin, he has worked at a variety of prestigious institutes including Harvard Medical School, Massachusetts General Hospital, the Cancer Science Institute of Singapore and the Netherlands Cancer Institute. Associate Professor Eichhorn's staff profileAssociate Professor Eichhorn's LinkedIn profileCurtin Health Innovation Research Institute websiteJoin Curtin UniversityThis podcast is brought to you by Curtin University. Curtin is a global university known for its commitment to making positive change happen through high-impact research, strong industry partnerships and practical teaching.Partner with CurtinStudy a research degreeStart postgraduate educationGot any questions, or suggestions for future topics?Email thefutureof@curtin.edu.auSocialshttps://twitter.com/curtinunihttps://www.facebook.com/curtinuniversityhttps://www.instagram.com/curtinuniversity/https://www.youtube.com/user/CurtinUniversityhttps://www.linkedin.com/school/curtinuniversity/ Transcripthttps://thefutureof.simplecast.com/episodes/breast-cancer-treatment/transcriptBehind the scenes teamJessica Morrison, HostAnita Shore, Executive ProducerAnnabelle Fouchard, ProducerDaniel Jauk, Episode Researcher, Recordist and EditorAlexandra Eftos, Assistant ProducerAmy Hosking, Social Media. Curtin University supports academic freedom of speech. The views expressed in The Future Of podcast may not reflect those of Curtin University. First Nations AcknowledgementCurtin University acknowledges the traditional owners of the land on which Curtin Perth is located, the Whadjuk people of the Nyungar Nation, and on Curtin Kalgoorlie, the Wongutha people of the North-Eastern Goldfields; and the First Nations peoples on all Curtin locations. MusicOKAY by 13ounce Creative Commons — Attribution-ShareAlike 3.0 Unported — CC BY-SA 3.0 Music promoted by Audio Library.

The official podcast from Diabetes Victoria, hosted by Jack Fitzpatrick Meet diabetes researcher Associate Professor John Wentworth. John receives funding from the Diabetes Australia Research Program (DARP) to develop an in-home islet autoantibody test for detecting type 1 diabetes. Similar to COVID-19 rapid antigen tests, this could mean a new way to identify type 1 diabetes in children and young adults who are at high risk quickly, easily, and at a lower cost. John works with the Walter and Eliza Hall Institute of Medical Research and collaborates with Melbourne Health/the Royal Melbourne Hospital, Lions Diabetes Foundation and JDRF. A great episode for anyone who is wondering what's new in the world of diabetes research Find us online at http://diabetesvic.org.au Subscribe in iTunes - https://apple.co/2Dj29B6 Subscribe on Spotify - https://spoti.fi/37F7ela Subscribe with iHeart Radio - https://ihr.fm/37nc8mV Contact us at podcasts@diabetesvic.org.au -- Post-production by Steve Visscher | Southern Skies Media for Howdy Partners Media | howdypartnersmedia.com.au/podcasts on behalf of Diabetes Victoria © 2022   See omnystudio.com/listener for privacy information.

My guest on this episode is Meg Salisbury, who joined me to celebrate Rare Disease Day. In 2016, Meg's daughter Ginger, was the 1st person in Australia and only the 34th person in the world, to be diagnosed with the rare genetic disease KAT6A. As of the beginning of 2022, there are now 13 people diagnosed with KAT6A in Australia. Meg is on the board of the KAT6A Foundation and also liaises with researchers in Melbourne at Murdoch Childrens Research Institute (MCRI) and Walter and Eliza Hall Institute of Medicine (WEHI), who are working on KAT6A. She also offers support to Australian families, in particular when their child is first diagnosed with KAT6A. In this interview Meg discusses what Rare Disease Day is, why it is important to speak out and raise awareness for rare diseases and what we can do to help. She also shares many insights into how KAT6A affects Ginger, the challenges and joys of being Ginger's Mum and how the parents of children with KAT6A have banded together to help each other. Meg is an absolute gem. She is an open book and is more than happy to answer questions and offer advice to those who need it.   Meg's Details: Instagram: @megmajella Facebook: Meg Salisbury   KAT6A information: Website: kat6a.org Instagram: @kat6afoundation Facebook: kat6afoundation   Podcast Details: Website: inspirationaltales.com.au Instagram: @inspirationaltalespodcast  

The team from the Walter and Eliza Hall Institute of Medical Research hopes it could lead to fast-tracked treatment options. See omnystudio.com/listener for privacy information.

A/Prof Jeanne Tie is the lower gastrointestinal medical oncology and trials lead at the Peter MacCallum Cancer Centre and senior research fellow in the Personalised Oncology Division at the Walter and Eliza Hall Institute of Medical Research. Stephanie and A/Prof Tie discuss personalising treatment for bowel cancer patients using prognostic and predictive biomarkers, including circulating tumour DNA. A/Prof Tie is passionate about the new frontier of cancer, the opportunities to improve patient outcomes and the importance of research and clinical trials.

In this episode of the Epigenetics Podcast, we caught up with Marnie Blewitt from the Walter and Eliza Hall Institute of Medical Research to talk about her work on the role of SMCHD1 in Development and Disease. The Laboratory of Marnie Blewitt focuses finding inhibitors or activators for the epigenetic regulator SMCHD1. Marnie Blewitt identified and characterized this protein during her PhD and the findings were published in 2008 in Nature Genetics. Since then, she and her team were able to investigate the function of this protein further. By doing so, they showed the involvement of SMCHD1 in cancer and several other diseases. Currently the lab is screening for small molecules that can act as inhibitors or activators of SMCHD1 the former as potential treatments for facioscapulohumeral muscular dystrophy, the latter for Prader Willi and Schaaf-Yang syndromes, both of which have no current targeted treatments.   References Blewitt, M. E., Gendrel, A.-V., Pang, Z., Sparrow, D. B., Whitelaw, N., Craig, J. M., Apedaile, A., Hilton, D. J., Dunwoodie, S. L., Brockdorff, N., Kay, G. F., & Whitelaw, E. (2008). SmcHD1, containing a structural-maintenance-of-chromosomes hinge domain, has a critical role in X inactivation. Nature Genetics, 40(5), 663–669. https://doi.org/10.1038/ng.142 Leong, H. S., Chen, K., Hu, Y., Lee, S., Corbin, J., Pakusch, M., Murphy, J. M., Majewski, I. J., Smyth, G. K., Alexander, W. S., Hilton, D. J., & Blewitt, M. E. (2013). Epigenetic Regulator Smchd1 Functions as a Tumor Suppressor. Cancer Research, 73(5), 1591–1599. https://doi.org/10.1158/0008-5472.CAN-12-3019 Gordon, C. T., Xue, S., Yigit, G., Filali, H., Chen, K., Rosin, N., Yoshiura, K., Oufadem, M., Beck, T. J., McGowan, R., Magee, A. C., Altmüller, J., Dion, C., Thiele, H., Gurzau, A. D., Nürnberg, P., Meschede, D., Mühlbauer, W., Okamoto, N., … Reversade, B. (2017). De novo mutations in SMCHD1 cause Bosma arhinia microphthalmia syndrome and abrogate nasal development. Nature Genetics, 49(2), 249–255. https://doi.org/10.1038/ng.3765   Related Episodes Epigenetics and X-Inactivation (Edith Heard) Biophysical Modeling of 3-D Genome Organization (Leonid Mirny) Unraveling Mechanisms of Chromosome Formation (Job Dekker)   Contact Active Motif on Twitter Epigenetics Podcast on Twitter Active Motif on LinkedIn Active Motif on Facebook Email: podcast@activemotif.com

Overview: In this episode we learn what a clinical trial is, how they are developed and why they are so important. We also learn about participating in clinical trials, factors to consider and what the process is to get involved. Speakers: Prof Mark Shackleton is the Director of Oncology at Alfred Health, a Professor of Oncology at Monash University, a Victorian Cancer Agency Clinical Research Fellow and Chair of Melanoma and Skin Cancer Trials Ltd. After training in medical oncology and at the Ludwig Institute in Melbourne, he undertook PhD studies at the Walter and Eliza Hall Institute of Medical Research and postdoctoral work at the University of Michigan, USA. He has received several major prizes for his research, most recently a 2016 Victorian Cancer Agency Clinical Research Fellowship and in 2012, he was awarded the Australian Science Minister's Prize for Life Scientist of the Year. Dr Megan Lyle is a Medical Oncologist with special interests in cancer immunotherapy, melanoma and other skin cancers and gastrointestinal malignancies.  Dr Lyle works at the Liz Plummer Cancer Care Centre at Cairns Hospital, Response Oncology, Far North Day Hospital and Cairns Private Hospital. Dr Lyle also holds a senior lecturer position with James Cook University. Dr Lyle received her Fellowship from the Royal Australasian College of Physicians in 2013 having undertaken medical oncology advanced training in Newcastle, NSW. She subsequently completed a clinical research fellowship at Melanoma Institute Australia, Sydney in 2013-14. Dr Lyle is published in major international peer reviewed journals, including the Journal of Clinical Oncology. Topics Covered In This Episode: What a clinical trial is, and why we need them Who can participate in clinical trials The types of clinical trials and who runs them Designing a clinical trial and establishing trial protocols  What is informed consent The different phases of clinical trials The role of human research ethics committees  How to find out more information about clinical trials Access to trials for remote and rural populations Increase in trials being run in regional areas Telehealth and clinical trials What is a placebo trial What happens after a trial concludes The future of clinical trials For More Information: The Spot On Podcast is brought to you by the Melanoma & Skin Cancer Advocacy Network (MSCAN) - who are providing a new, innovative approach to tackle Australia's national cancer. MSCAN engages with Australia's leading clinicians, researchers and advocates with the aim of increasing the knowledge of those affected by a diagnosis.  MSCAN is grateful to the clinicians interviewed in our podcast series. They have all provided their time and input freely and independently.    The content discussed in these episodes is for information purposes only and should not be considered as medical advice. Please make sure you speak with a medical professional for advice relating to your own specific situation.

Since COVID-19 hit, the science of modelling has moved into the spotlight. Today we're talking about the reasons for the difference between two recently published examples from the Doherty Institute and a preprint from ANU. Professor Ivo Mueller, an epidemiologist at the Walter and Eliza Hall Institute in Melbourne, working across population health and immunity, explains the assumptions inherent in each. At a time where modelling is so prevalent, it's important to build modelling literacy and unpack the methodology of modelling, so we can all understand what they can and can't do! Today's interview is hosted by Cosmos Magazine editor Gail MacCallum.Find the science of everything at the Cosmos Magazine website Subscribe to Cosmos Magazine (print) or the Cosmos WeeklyWatch and listen to all our Cosmos Briefings

Thank you for tuning into another episode of Talking Gut! In today's episode I sat down and talked to Dr Zina Valaydon on Hepatology and the Liver. Dr Zina Valaydon is a consultant gastroenterologist and hepatologist. She is the head of the Hepatology service at the Western Hospital in Melbourne Australia.  Zina graduated from The University of Melbourne with a double degree in Medicine and Surgery and Biomedical Science. She completed her physician training at the Royal Melbourne Hospital. She undertook specialist training in Gastroenterology and Hepatology at St. Vincent's Hospital and the Austin Hospital and is a fellow of the Royal Australasian college of Physicians Zina has a PhD in hepatology from the University of Melbourne in collaboration with the Walter and Eliza Hall Institute. What an episode I have install for you. Soo much cool and interesting information on the Liver. What an Organ! In today's episode, we discussed everything from what the liver is, what it does, the different diseases and treatments, the effect of alcohol and constipation has on the liver, to fatty liver and detox diets, and as always, so much more. Please enjoy my conversation with Dr Zine Valaydon

Professor Marc Pellegrini is the head of the Infectious Diseases and Immune Defence division of the Walter and Eliza Hall Institute of Medical Research. He received his PhD from the University of Melbourne. His primary interest is in host pathogen interactions and how they inform the development of therapies for infectious diseases. On this episode we discuss, amongst other things, vaccines and the origins of COVID-19.

Tuberculosis is the world's longest-running pandemic and kills about two million world citizens a year. While often it is the immune response to bacterial infection that's so dangerous, tuberculosis adds a complexity that is especially challenging. Anna Coussens zeros in on several of these complexities in her research. Listen in and learn How the immune response differs dramatically among those infected and how Dr. Coussens is trying to understand why, What is the disease progression and ways the immune response harms the infected individual, and How she is working on "host-directed therapy" as a way to combat the complexities of the disease. Anna Coussens is a Laboratory Head in the Division of Infectious Diseases and Immune Defense with the Walter and Eliza Hall Institute of Medical Research. Her work in infectious diseases microbiology focuses specifically on tuberculosis as an immunologist. Because TB is a dominant problem in lower socioeconomic countries, it is often forgotten about in other areas. This has pushed treatment down on the list of common infectious diseases, but Dr. Coussens is working to change this.  She helps listeners understand why Mycobacterium tuberculosis is still the cause of so much illness, explaining the interplay of immunity and infection. It can trick T-cells into not recognizing its presence in infected cells through an extra-cellular vesicle sleight of hand. Furthermore, it has a very slow growth pattern, which makes it both hard to treat and hard to study in lab conditions. Many infected persons can exhibit a strong response and inflammation for years before doctors can detect bacteria in their sputum. Dr. Coussens is trying to understand why different cells can react in such varied ways to the bacteria. Her research aims to find a way to treat the individual and the immune dysfunction of that individual through "host-directed therapy." She hopes to help resolve inflammation that might lead to better outcomes for treatment. People who have had TB are actually at a high risk for getting it again, which perpetuates the disease in high-burden areas. Listen as one researcher describes her hard work to bring better treatment to these communities. For more about her work, follow her on Twitter as @AnnaCoussens and see her web page at WEHI. Available on Apple Podcasts: apple.co/2Os0myK

This podcast explores an exciting discovery with implications for all neurodegenerative diseases and it centers on inflammation prevention. While inflammation is a known player in autoimmune diseases, researchers like Seth Masters have identified an inflammatory element in amyotrophic lateral sclerosis (ALS). Listen and learn Mechanisms of auto inflammatory diseases versus autoimmune, The role of the innate immune system in causing disease, and Why connecting inflammation with ALS offers significant hope for therapies to slow down disease progression for all neurodegenerative diseases. Seth Masters is an associate professor with the Walter and Eliza Hall Institute of Medical Research in Melbourne. His lab work centered on auto inflammatory syndromes and diseases from the context of autoimmunity—when the body is fighting against itself. Then, as with many significant moments in science, they took a step back and looked at the larger picture: they examined all the knowledge they'd acquired and asked if there were any other diseases in which this might play a role. Neurodegenerative diseases of the brain stood front and center as a strong possibility.  ALS is a particular form of neurodegenerative disease that's struck well-known figures like Stephen Hawking. These patients' muscles are not working because of damage impeding motor neuron function. Dr. Masters' group found that these motor neurons are sensitive to inflammation and caused them to die. Therefore, if doctors can prevent or slow down this inflammation, it will have a significant effect in slowing down the disease progression. He says that they are in safety phase 1 trials for drugs that will block that inflammation. He explains methodology for testing these drugs as well as an interesting description of how they hope to eventually identify the inflammation trigger. He tells listeners that may suffer from these diseases that there is "great hope" in what they've discovered and will make significant therapeutic strides. Listen in for more of this exciting news! For more about his work, see his page on the institute's website: wehi.edu.au/people/seth-master Available on Apple Podcasts: apple.co/2Os0myK

In this episode, I talk to Dr Onisha Patel, who is a structural biologist at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, Australia I speak to her about: – How she got into science from her interest in art – What inspired her growing up – Structural Biology and what […]

A special COVID edition of Science with Dr Karl this week. We answer all your questions with the host of the ABC's Coronacast Tegan Taylor & Professor Marc Pellegrini - joint head of infectious diseases and immune defence at the Walter and Eliza Hall Institute in Melbourne.

A special COVID edition of Science with Dr Karl this week. We answer all your questions with the host of the ABC's Coronacast Tegan Taylor & Professor Marc Pellegrini - joint head of infectious diseases and immune defence at the Walter and Eliza Hall Institute in Melbourne.

Melbourne researchers are working on a promising new class of treatments which may be able to give people with Motor Neuron Disease (MND) another 10 years of life. Researchers at the Walter and Eliza Hall Institute have been working on the treatments which they think will dramatically slow the progression of the disease. The team discovered how inflammation in MND is triggered, and found by blocking an immune sensor they could prevent much of that inflammation in cells. Associate Professor Seth Masters, from the Walter and Eliza Hall Institute, told Gareth Parker that "the treatments won’t cure the disease or stop it from starting but they will slow the disease.” See omnystudio.com/listener for privacy information.

Associate Professor Seth Masters, from the Walter and Eliza Hall Institute, says the new class of treatments which he and other researchers are working on won't be a cure, but they could extend the lives of people with MND. See omnystudio.com/listener for privacy information.

CHURCH IS CHANGINGAs the effects of COVID‐19 continue to change the landscape of church ministry, some churches are considering permanent changes. One Baptist Church has seen online participation now three times larger than prepandemic in-person church attendance. Church pastor, Robby Gallaty, says they have begun the process of creating a permanent online church ministry. Pastor Gallaty says that churches predominantly dependent upon a building are going to have a hard time transitioning into the future. ‘Change is constant’, he says, but as the Body of Christ, there must be a willingness to reach as many people as possible even if it’s uncomfortable and different. If the Church doesn’t have a robust online presence it is going to miss where the people are.MESSAGE OF HOPE FOR TASMANIAIn May 2021, Will Graham will be bringing a message of hope to Tasmania. New Life reports that the Billy Graham Evangelistic Association has been preparing for the upcoming Celebration, which will be hosted in the cities of Hobart and Launceston and streamed online. FOCUS OF A MAN OF FAITHHeart Of The Nation, a feature in The Australian newspaper’s Weekend Magazine written by Ross Bilton, tells of an up-and-coming young medical researcher, Dr Caleb Dawson, who works at the Walter and Eliza Hall Institute in Melbourne. Apparently, he is ‘probing the mysteries of cancer and the immune system using the esoteric techniques of “3D confocal fluorescence microscopy” in which special dyes and lasers are brought to bear on tissue samples, revealing ever-deeper layers of reality. Dawson’s curious gaze isn’t just detached and scientific. He sees beauty in there too; he sees art. And he sees something even deeper: the hand of God. For as well as being a scientist, Dawson, 28, is also a man of faith, a guitar-strumming Christian who declares his belief in the resurrection of Jesus.

CHURCH IS CHANGINGAs the effects of COVID‐19 continue to change the landscape of church ministry, some churches are considering permanent changes. One Baptist Church has seen online participation now three times larger than prepandemic in-person church attendance. Church pastor, Robby Gallaty, says they have begun the process of creating a permanent online church ministry. Pastor Gallaty says that churches predominantly dependent upon a building are going to have a hard time transitioning into the future. ‘Change is constant’, he says, but as the Body of Christ, there must be a willingness to reach as many people as possible even if it’s uncomfortable and different. If the Church doesn’t have a robust online presence it is going to miss where the people are.MESSAGE OF HOPE FOR TASMANIAIn May 2021, Will Graham will be bringing a message of hope to Tasmania. New Life reports that the Billy Graham Evangelistic Association has been preparing for the upcoming Celebration, which will be hosted in the cities of Hobart and Launceston and streamed online. FOCUS OF A MAN OF FAITHHeart Of The Nation, a feature in The Australian newspaper’s Weekend Magazine written by Ross Bilton, tells of an up-and-coming young medical researcher, Dr Caleb Dawson, who works at the Walter and Eliza Hall Institute in Melbourne. Apparently, he is ‘probing the mysteries of cancer and the immune system using the esoteric techniques of “3D confocal fluorescence microscopy” in which special dyes and lasers are brought to bear on tissue samples, revealing ever-deeper layers of reality. Dawson’s curious gaze isn’t just detached and scientific. He sees beauty in there too; he sees art. And he sees something even deeper: the hand of God. For as well as being a scientist, Dawson, 28, is also a man of faith, a guitar-strumming Christian who declares his belief in the resurrection of Jesus.

Prof Pasricha is a haematologist at Royal Melbourne Hospital and scientist at the Walter & Eliza Hall Institute of Medical Research. In this he speaks about the role of hepcidin in iron regulation, iron deficiency and anaemia, iron overload and haemochromatosis, and thalassaemia.Support the show (https://haemochromatosis.org.au/supportus/donate/)

In this episode, we are joined by Biomedical Animator Drew Berry. Drew creates beautiful, accurate visualizations of the dramatic cellular and molecular action that is going on inside our bodies. Beginning his career as a cell biologist, Drew's raw materials are technical reports, research data and models from scientific journals. As an artist he works as a translator, from abstract and complicated scientific concepts into vivid and meaningful visual journeys. Since 1995 he has been a biomedical animator at the Walter and Eliza Hall Institute of Medical Research in Australia. His animations have been exhibited at venues such as the Guggenheim Museum, Museum of Modern Art, and the Royal Institute of Great Britain. In 2010 he received a MacArthur Fellowship “Genius Grant".   In this episode, we dissect Drew's journey as an animator and pull back the veil on the level of detail, research, and technical expertise needed to produce stunning and accurate representations of cellular and molecular processes.   Links to Animations mentioned in the Podcast Episode: DNA: https://youtu.be/7Hk9jct2ozY Apoptosis: https://youtu.be/DR80Huxp4y8 Malaria Life-cycle: https://youtu.be/1v55yg0RfoY TED: https://youtu.be/WFCvkkDSfIU   Drew Berry YouTube animation playlilst https://www.youtube.com/playlist?list=PLD0444BD542B4D7D9 drewberry.com wehi.tv library of animations for download HHMI Biointeractive.org Bjork music video https://www.youtube.com/watch?v=Yn8AC8z2adU David Goodsell (Molecular illustrator, my primary inspiration and living deity of visualizing our molecular interior) https://ccsb.scripps.edu/goodsell/ Gael McGill (Harvard Medical School, Biomedical animation tools and tutorials) Clarafi.com Eric Keller (Freelancer, excellent bioemedical animator and teacher for cinema visual effects)  https://www.bloopatone.com

Jocelyn Bell; and 20 PhDsAstrophysicist and discoverer of the first radio pulsars in 1967, Jocelyn Bell Burnell, joins Dr. Shane; and it's another 20 PhDs special, with the following PhD candidates talking to Shane about the where, what, why of their studies:Amy Coe, University of Melbourne: Ceasing anti-depressantsNilakhi Poddar, The University of Melbourne: Arsenic biosensor James Rule, Monash University/Museums Victoria: fossilised sealsJacinta Humphrey, La Trobe University: urban bird communities.Emily Ramage, University of Newcastle: co designed health interventions for stroke survivorsEleonora Comeo, University of Nottingham and Monash University: fluorescent moleculesHamdi Jama, Monash University: The connection of dietary fibre to heart diseaseYara Toenders, Orygen (Centre for Youth Mental Health) & University of Melbourne: DepressionZoe Jenkins, Swinburne University of Technology and St. Vincent’s Hospital, Melbourne: Cardio vascular & anorexiaShammi Akter Ferdousi, Deakin University: Non flammable batteriesCassie Hatzipantelis, Monash Institute of Pharmaceutical Sciences: Anti psychoticsLong Nguyen, The University of Melbourne: Enhanced wound healing.Kate senior, The University of Melbourne: Better managed fire prone landscapesWessel Burger, Monash Institute of Pharmaceutical Sciences: Improving clinical translation of drugsEveline Mu, Swinburne University: Facial emotion processing in individuals with low and high autistic tendenciesSimone Stevenson, Deakin University: Metrics of biodiversity lossMichelle Clark, The Walter and Eliza Hall Institute of Medical Research: new treatments for LeishmaniasisClaire Young, Deakin University: Treating depression with diet changeMehri Barabadi, Hudson institute of medical science, treating Multiple sclerosis using cells from the placenta Samantha Davis, Peter DOherty Institute for Infection and Immunity: new HIV therapiesMaria Petraki, Hudson Institute: Biomarkers to monitor ovarian cancerEttore Camerlenghi, Monash University: What a society looks like for birdsProgram page: Einstein-A-Go-GoFacebook page: Einstein-A-Go-GoTwitter: Einstein-A-Go-GoAnd live every Sunday at 11:00a.m AEST on RRR 102.7mHz FM.

Dr Margs Brennan is a cancer researcher, studying how blood cancers develop and how cells avoid dying. She's also currently living in Melbourne during the second COVID-caused lockdown, balancing research and care for an 8 month old baby. Margs and I did our PhD in the same lab (the Herold lab at the Walter & Eliza Hall Institute. You can find out more about that here: https://www.wehi.edu.au/people/marco-herold/322/dr-marco-herold-lab-team or via Twitter @WEHI_research @MarcoHerold_JFor more information about Nice to Know, follow me on Twitter @RobynSciences or email nicetoknowthepodcast@gmail.comThis series was made with the support of the Marie Curie Alumni Association.

Joint Head of Infectious Diseases and Immune Defence from the Walter and Eliza Hall Institute, Professor Marc Pellegrini, explains how the groundbreaking new test works and how it will change the way diseases are diagnosed.

In this week's episode of Anything but Square, we are joined by Dr Caleb Dawson, Walter and Eliza Hall Institute researcher, to discuss new immune cells revealed in breast ducts. The WEHI research team has discover a new type of immune cell that helps to keep breast tissue healthy.    The research was led by Dr Dawson, Professor Geoff Lindeman, Professor Jane Visvader and Dr Anne Rios, now based at the Princess Maxima Center for Pediatic Oncology, Netherlands. It was published in the journal Nature Cell Biology.    SUBSCRIBE to Fed Square: https://bit.ly/3ioxRjr   World-class art galleries and installations. A diverse range of food and drink. Thrilling, extraordinary events that capture the hearts of Melburnians year after year. Fed Square is anything but square. Since opening in 2002, Fed Square has seen more than 100 million visits and been named the 6th Best Public Square in the World. Frankly, we're slaying out here and it's nice to be recognised.   Facebook: https://www.facebook.com/FedSquare/ Twitter: https://twitter.com/FedSquare Instagram: https://www.instagram.com/fed.square/ What's On at Fed Square: https://fedsquare.com/

Melbourne's Walter and Eliza Hall Institute is starting a trial to find out if it can stop healthcare workers getting the disease.

New research findings into Neanderthals; cool new facts about rhinoceroses; and what the discovery of ancient teeth in Peru means. Also: Professor John Dewar, Vice-Chancellor of Latrobe Uni, discusses the role of the University in a pandemic; Dr Holly Barker, from the Walter and Eliza Hall Institute talks about the Stafford Fox Rare Cancer Program (SFRCP); and Eliza Colgrave, PhD Scholar from the Royal Women’s Hospital discusses her research on endometriosis. With presenters Dr. Shane, Chris KP, Dr Jen and Dr Euan.Remember, Science is everywhere.

Professor Len Harrison is a clinician-scientist and NHMRC Senior Investigator in the Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research (‘WEHI'). From 1987-2010 he headed the Autoimmunity and Transplantation Division at WEHI and was Director of the Burnet Clinical Research Unit and Department of Clinical Immunology and Allergy at the Royal Melbourne Hospital. He has written several books and authored or co-authored over 560 research papers on immune mechanisms of disease. His research is now focused on how the environment and genes interact to cause childhood diseases such as type 1 diabetes, coeliac disease and allergies. His awards for research include the C.J. Martin Fellowship, Wellcome Australia Medal, Susman Prize, Kellion Medal and the international Rumbough Award for scientific excellence.

Dr Shane, Dr Linden, Dr Laura and Dr Ray bring you the week’s hottest science, including a new acoustic observatory, taking the pulse of a blue whale, and training E. coli to eat CO2.They talk to Carra Simpson, PhD Candidate at the Melbourne School of Psychological Sciences at the University of Melbourne, about the high rates of co-occurence between mental health and gastrointestinal disorders.They interview Narelle Keating, PhD Candidate at the Walter and Eliza Hall Institute of Medical Research, about her work investigating Interferon and its use in helping our immune systems.Finally, they chat with Georgia Atkin-Smith, postdoc researcher at the La Trobe Institute for Molecular Science at La Trobe University, about a protein that is responsible for coordinating cell death.Remember, “Science is everywhere”, including:Program page: Einstein-A-Go-GoFacebook page: Einstein-A-Go-GoTwitter: Einstein-A-Go-Goand live every Sunday at 11:00a.m AEST on RRR 102.7mHz FM.

Dr Yuri Shibata is one of researchers coming to Walter and Eliza Hall Institute of Medical Research, abbreviated as WEHI, from all over the world. WEHI is Australia's oldest medical research institute. Dr Shibata talked about a bit of her work and Melbourne life. Broadcast on 2 Nov 2019 - 柴田佑里博士はメルボルンにあるオーストラリアで一番古い医学研究所、ザ・ウォルター・アンド・イライザ・ホール医学研究所、通称WEHIであるタンパク質の研究を続けています。博士に仕事のことやメルボルンでの生活などについて聞きました。2019年11月２日放送

Fiona Trafford-Walker is one of the world’s most respected asset consultants. Trafford-Walker is a founding member of Frontier Advisors and has advised many of Australia’s largest pension funds on their investment strategy. Currently, she is a Director and member of the Investment Committee at Frontier, but has announced to leave the company on 6 December 2019 to focus on her directorships. She is a Non-Executive Director at the Link Group, Prospa Group and the Victorian Funds Management Corporation and a member of the Investment Committee at the Walter and Eliza Hall Institute. Trafford-Walker was named as one of the Top 10 global asset consultants by CIO Magazine from 2013 to 2016 inclusive. She was also announced as a winner in The AFR and Westpac 100 Women of Influence Awards for 2016 in the Board/management category. In this podcast, we look back on her 25 years with Frontier, her career as an asset consultant and discuss a variety of topics, including manager selection, asset allocation and the changing landscape pension funds face today. Overview Fiona Trafford-Walker podcast: 2:30 I’m an accidental asset consultant 4:30 You’re named as one of the most influential asset consultants in the industry. What makes a good asset consultant? 5:35 You have to be willing to collaborate 7:00 Technical skills are very important, but equally important is time in the markets 7:30 The changing role of asset consultants over the years 9:30 As asset consultants have increased their senior staff, have conversations become more focused on strategy? 10:30 There is still the need to have a blend of specialist and generalist skills 11:50 Are we already heading to having a panel of asset consultants? 13:00 Is there a good balance between the time spend on manager research and that on asset allocation? 14:30 What type of data should inform changes in asset allocation? 16:00 There is not much you can do about geopolitical risk; predicting what politicians are going to do next is pretty hard. 16:30 But trade wars are a real thing that have an effect on markets 18:00 Are the struggles of active managers, particularly value managers, structural or cyclical? 19:00 There seems to be a need to tweak the value process to allow for the new capital-light business models. But at what stage do you get style drift? 21:30 Frontier Advisors took the decision to build a platform with all their research on it, quite a brave step in an era where softcopies get distributed easily. 26:00 You spent some time arguing for lower fees in the industry. Are we at the right level? 27:30 The real change has been the internalisation of asset management by some funds. 29:00 Can internalisation refocus asset management on the long term? 30:00 Bottom draw mandates 31:00 To what extent should asset owners engage with the companies they invest in? You are on a number of boards and see both sides? 33:00 Governance certainly has changed as asset owners realise they are the beneficial owners 35:00 To what degree can you divest from companies as a fiduciary? 38:00 The challenge of developing retirement products 41:00 At the moment, the willingness to do things together [as funds] isn’t there. 42:00 What is next in store for you? 44:00 What issues come up in mentoring new asset consultants?

 Take a deep breath, folks - this one's a biggie! Kate's spent more time in hospitals than most, and Bumpy and the Wise Old Wolfhound is a window to get real and raw.  You really just have to listen to understand - but once you have (and once you've got whatever it is out of your eye), if you want to check out the organisations Kate mentions, they're Syndromes Without a Name Australia, and the Walter and Eliza Hall Institute of Medical Research. And for more about why Kate and co have spent so much time in hospitals, Kate shares here.  When we interviewed Joe Brumm he told us that Bumpy was really personally special to him. Well, us too - thanks to Joe and the whole Ludo Studio team for making it so very perfect.  ++ Gotta Be Done is ex-journos and Melbourne mums Kate McMahon and Mary Bolling, as we deep-dive every Bluey episode, with plenty of detours into mama life, childhood memories, and everything else we're bingeing, too! Follow us on Insta at @blueypod @marytbolling @katejmcmahon or on Twitter at @blueypodcast - and use #blueypod to join in.

How do you turn your STEM studies into a living wage? Or even better - how do you turn your golden STEM idea into actual gold? You might just find out in this episode of Secret Life of STEM. We talk to select entrepreneurs from the Melbourne Accelerator Program, a start up fund that helps grow Australian businesses. These people combined their knowledge of STEM and business, and are now using it to improve the world with the companies Beyond Ag and Curvecrete. You'll also hear from a teacher that turned her STEM skills into an automated roll-marking system. Neat! Also in this episode, our reverse engineer Danielle Goulopolous discovers what Google knows about you - and how to reduce that secret knowledge. GUESTS: ● Phoebe Gardner, Co-Founder - Beyond Ag ● Alex Arnold, Co-Founder - Beyond Ag ● Greg Nyilasy, Academic, Management and Marketing, University of Melbourne ● Warren Rudd, Co-Founder - Curvecrete ● Daniel Prohasky, Co-Founder - Curvecrete ● Danielle Goulopolous, Media and Communications Student ● Martin Elhay, Senior Business Development Manager, University of Melbourne ● Zoe Milne, Co-founder - Loop Learn LINKS: ● The Melbourne Accelerator Program - https://www.themap.co/ ● Beyond Ag - https://www.themap.co/portfolio/beyond-ag ● The Wade Institute of Entrepeneurship - https://www.ormond.unimelb.edu.au/about/wade-institute-entrepreneurship/ ● Curvecrete - https://curvecrete.com/ ● What does Google know about you? - https://medium.com/productivity-in-the-cloud/6-links-that-will-show-you-what-google-knows-about-you-f39b8af9decc ● The Lean Startup - http://theleanstartup.com/ ● Study Business and Economics at UniMelb - https://study.unimelb.edu.au/find/interests/business-and-economics/ ● Loop Learn Automated Roll-Marking - https://www.looplearn.net/ ● Walter and Eliza Hall Institute - https://www.wehi.edu.au/ ● Find a course - https://study.unimelb.edu.au CREDITS: Guest Host: Erin Grant Episode Host/Producer/Editor: Buffy Gorrilla Supervising Producer/Science Advisor: Dr. Andi Horvath Assistant Producer: Silvi Vann-Wall Additional Editing: Arch Cuthbertson CONTACT: podcasting-team@unimelb.edu.au

How do you turn your STEM studies into a living wage? Or even better - how do you turn your golden STEM idea into actual gold? You might just find out in this episode of Secret Life of STEM.We talk to select entrepreneurs from the Melbourne Accelerator Program, a start up fund that helps grow Australian businesses. These people combined their knowledge of STEM and business, and are now using it to improve the world with the companies Beyond Ag and Curvecrete. You’ll also hear from a teacher that turned her STEM skills into an automated roll-marking system. Neat!Also in this episode, our reverse engineer Danielle Goulopolous discovers what Google knows about you - and how to reduce that secret knowledge.GUESTS:● Phoebe Gardner, Co-Founder - Beyond Ag● Alex Arnold, Co-Founder - Beyond Ag● Greg Nyilasy, Academic, Management and Marketing, University of Melbourne● Warren Rudd, Co-Founder - Curvecrete● Daniel Prohasky, Co-Founder - Curvecrete● Danielle Goulopolous, Media and Communications Student● Martin Elhay, Senior Business Development Manager, University of Melbourne● Zoe Milne, Co-founder - Loop LearnLINKS:● The Melbourne Accelerator Program - https://www.themap.co/● Beyond Ag - https://www.themap.co/portfolio/beyond-ag● The Wade Institute of Entrepeneurship - https://www.ormond.unimelb.edu.au/about/wade-institute-entrepreneurship/● Curvecrete - https://curvecrete.com/● What does Google know about you? - https://medium.com/productivity-in-the-cloud/6-links-that-will-show-you-what-google-knows-about-you-f39b8af9decc● The Lean Startup - http://theleanstartup.com/● Study Business and Economics at UniMelb - https://study.unimelb.edu.au/find/interests/business-and-economics/● Loop Learn Automated Roll-Marking - https://www.looplearn.net/● Walter and Eliza Hall Institute - https://www.wehi.edu.au/● Find a course - https://study.unimelb.edu.auCREDITS:Guest Host: Erin GrantEpisode Host/Producer/Editor: Buffy GorrillaSupervising Producer/Science Advisor: Dr. Andi HorvathAssistant Producer: Silvi Vann-WallAdditional Editing: Arch CuthbertsonCONTACT:podcasting-team@unimelb.edu.au

Dr Tye-Din is a gastroenterologist with a clinical and research interest in Coeliac disease. He heads the Coeliac Research Lab at the Walter and Eliza Hall Institute, runs a Coeliac clinic at the Royal Melbourne Hospital and is an Honorary Research Fellow at the Murdoch Children’s Research Institute. His PhD employed feeding studies to characterise gluten immunity that underpinned development of a novel immunotherapy for Coeliac disease, Nexvax2. His research interests include understanding the immune and genetic basis for coeliac disease and how gluten tolerance is lost, the role of the microbiome, understanding why the gluten-free diet can fail, and developing and testing novel diagnostics and treatments. He is on the editorial board of Alimentary Pharmacology and Therapeutics and consults for an industry partner (ImmusanT Inc.) who are leading the development of Nexvax2. Jason chairs the Medical Advisory Committee of Coeliac Australia and is involved in patient advocacy, clinical guideline development and medical education. In todays talk, we covered a lot. There was so much about coeliac disease that I didn’t know, and so, I think a lot of people, medical professionals as well as individuals managing this disease, will find this episode really interesting and helpful. So what did we cover? We talked about What Coeliac disease is? Its Incidence and prevalence ? Age of onset ? What the symptoms are ? The potential complications of undiagnosed untreated coeliac disease? Why a gluten free diet may sometimes be unsuccessful in reducing complications The different ways to diagnose Coeliac disease? Why Coeliac disease can be under diagnosed The overlap between Coeliac disease and functional gut disorders The difference between Coeliac disease and Non-Coeliac Gluten Hypersensitivity We also talking about his exciting new research in developing a vaccine, called the Nexvax2 We talked about the research looking at utilising the hook worm to manage the disease What is important for a person managing Coeliac disease or newly diagnosed to know? What would be take home message for health professionals ? and...a whole lot more... Please enjoy my conversation with Dr Jason Tye-Din

STEM is a multidisciplinary pursuit. The truth is you can't separate the Arts and Humanities from the Sciences, nor the Sciences from the Arts. It's particularly exciting to see the Arts and Sciences collide. In this episode, you will meet women using both the science and the arts to weave together fascinating careers. You'll discover that when multidisciplinary teams work together, they come up with extraordinary things. It's very likely if you work as a scientist you will work with artsy types and vice versa. We almost called this podcast episode The Secret life of STEAM because STEM is really STEAM and that would have been a SmART title. Also, in this episode: Danielle Goulopoulos, a University of Melbourne Arts student explores home assistants in the Reverse Engineering segment. GUESTS: Dr Leah Heiss, Designer and Academic, Wearable Health Technology & Human Centred Design, RMIT University Dr Mary Mathias, Community Manager for EngineerGirl and the Online Ethics Center, National Academy of Engineering, USA. Dr Nicki Cranna, Scientific Education Coordinator, Walter and Eliza Hall Institute of Medical Research LINKS: Bachelor of Science at the University of Melbourne https://study.unimelb.edu.au/find/courses/undergraduate/bachelor-of-science/ Bachelor of Biomedicine at the University of Melbourne https://study.unimelb.edu.au/find/courses/undergraduate/bachelor-of-biomedicine/ Careers and Employability at the University of Melbourne https://students.unimelb.edu.au/careers CREDITS: Guest Host: Danielle Goulopoulos Episode host, Supervising Producer, Science advisor: Dr Andi Horvath Producer, Editor: Buffy Gorrilla Assistant producer: Silvi Vann-Wall Additional editing: Arch Cuthbertson CONTACT podcasting-team@unimelb.edu.au

STEM is a multidisciplinary pursuit. The truth is you can’t separate the Arts and Humanities from the Sciences, nor the Sciences from the Arts. It’s particularly exciting to see the Arts and Sciences collide.In this episode, you will meet women using both the science and the arts to weave together fascinating careers. You’ll discover that when multidisciplinary teams work together, they come up with extraordinary things.It's very likely if you work as a scientist you will work with artsy types and vice versa.We almost called this podcast episode The Secret life of STEAM because STEM is really STEAM and that would have been a SmART title.Also, in this episode: Danielle Goulopoulos, a University of Melbourne Arts student explores home assistants in the Reverse Engineering segment. GUESTS:Dr Leah Heiss, Designer and Academic, Wearable Health Technology & Human Centred Design, RMIT UniversityDr Mary Mathias, Community Manager for EngineerGirl and the Online Ethics Center, National Academy of Engineering, USA.Dr Nicki Cranna, Scientific Education Coordinator, Walter and Eliza Hall Institute of Medical ResearchLINKS:Bachelor of Science at the University of Melbourne https://study.unimelb.edu.au/find/courses/undergraduate/bachelor-of-science/Bachelor of Biomedicine at the University of Melbourne https://study.unimelb.edu.au/find/courses/undergraduate/bachelor-of-biomedicine/Careers and Employability at the University of Melbourne https://students.unimelb.edu.au/careersCREDITS:Guest Host: Danielle GoulopoulosEpisode host, Supervising Producer, Science advisor: Dr Andi HorvathProducer, Editor: Buffy GorrillaAssistant producer: Silvi Vann-WallAdditional editing: Arch CuthbertsonCONTACTpodcasting-team@unimelb.edu.au

Einstein A Go Go 31st March 2019Dr Linden, Dr Lauren, Dr Ray & Dr ShaneScience News: Memory in the seeds of plants, new techniques in breast cancer imaging, Mineral photo voltaic cells, the search for dark matter.First guest: Dr Jess Borgers, Monash University Department of Immunology and Pathology. Participating in a new TV Show called Smart Brains of Australia.Second Guest: Professor John Langford, University of Melbourne. Modelling Melbournes Water usage and planning for the future.Third Guest: Halina Pietrzak Education Representative, WEHI Student Association PhD candidate, Hansen Laboratory Infection and Immunity Division The Walter and Eliza Hall Institute of Medical Research. The pathogenesis of severe malaria infection and how malaria parasites can manipulate our ability to launch a protective immune response, and recall this response in future infections.Remember, Science is everywhere, including:Website, Facebook, Twitter, Podcasts& every Sunday at 11a.m AEST on RRR 102.7mHz FM

In the episode we were joined by two very special guests, Associate Professor John Wentworth and Belinda Moore. John is a visiting Endocrinologist and the Royal Melbourne Hospital, a senior diabetes researcher at the Walter and Eliza Hall Institute of Medical Research, lead for TrialNet in Australia and New Zealand and he is involved with the ENDIA study. Belinda is a Research Nurse Study Coordinator at ENDIA, a credentialed Diabetes Educator, Peadiatric Nurse and Registered Midwife. In this episode we covered lots of interesting topics including how diabetes affects Aboriginal communities, current research into the detection and cure of type 1 diabetes, diabetes in pregnancy and how diabetes affects mental health.

Dr Krystal, Dr Ailie, and Dr Ray join Dr Shane in the studio. First guest (on the phone) isDr Simon ClulowfromMacquarie University. Cane toads are picking up some shady habits,Toads in Western Australia have been spotted awake and active during the day in deeply shaded habitats, despite thespecies usually being nocturnal in Australia and other parts of the world. However nearby cane toad populations atmore exposed sites remained only active at night. This suggests that cane toads are particularly good at changingtheir behaviour in response to their environment, something known as behavioural plasticity, which might assist theirinvasive spread into new environments. Second guest (in the studio) isDr Shalin Naik fromthe Walter and Eliza Hall Institute of Medical Research. A cutting-edge technique called cellular barcoding has been used to tag, track and pinpoint cells responsible for thespread of breast cancer from the main tumour into the blood and other organs. The technique also revealed howchemotherapy temporarily shrinks the number of harmful cells, rather than eliminating them, explaining how thecancer could eventually relapse. Final guest isDr Ashlea Wainwright,Senior Technical Officer,School of Earth, Atmosphere & Environment atMonash University. Zircons are incredibly resilient and it takes a lot to destroy them. Which means that the oldest pieces of Earth wehave are zircons from the Jack Hills in Western Australia, some of which have been dated at 4.4 billion years old (theEarth is 4.5 billion years old). So they are the only clues we have to the very beginning of Earth's history.

Over the Australian summer, we'll be replaying some of your favourite episodes. We bet you will learn something you missed the first time. Dr Melissa Davis is a computational biologist and Laboratory Head of the Bioinformatics Division at the Walter and Eliza Hall Institute. Driven by a passion to make the cancer diagnosis a less devastating one, Melissa and her team are at the cutting edge of bioinformatic studies aimed to reduce the traumatic side effects patients experience while being treated for cancer.In this week's Success Story, Melissa shares with Catherine Robson the role sophisticated data analytics and mathematical modelling play in revolutionising cancer treatment and why a difficult financial decision led to the career she loves today.

A brain injury like a stroke or a neuro degenerative condition like Huntingdon's or Parkinson’s disease can be a long and arduous ordeal. It can be difficult to diagnose and there are no clear treatments, but scientists are working hard to solve it. We find out about the important role Glial cells play in supporting neurons and how things can go wrong if they are disrupted. We also find out about ways to use the abundance of Glial cells to make new neurons. Plus we get a better understanding of cell death and repair and the roll proteins can play in slowing down those processes to give your brain time to recover. Mikhail Osipovitch, Andrea Asenjo Martinez, John N. Mariani, Adam Cornwell, Simrat Dhaliwal, Lisa Zou, Devin Chandler-Militello, Su Wang, Xiaojie Li, Sarah-Jehanne Benraiss, Robert Agate, Andrea Lampp, Abdellatif Benraiss, Martha S. Windrem, Steven A. Goldman. Human ESC-Derived Chimeric Mouse Models of Huntington’s Disease Reveal Cell-Intrinsic Defects in Glial Progenitor Cell Differentiation. Cell Stem Cell, 2018; DOI: 10.1016/j.stem.2018.11.010 Walter and Eliza Hall Institute. (2018, December 20). Parkinson's disease protein buys time for cell repair. ScienceDaily. Retrieved January 5, 2019 from www.sciencedaily.com/releases/2018/12/181220080000.htm Penn State. (2018, November 5). New gene therapy reprograms brain glial cells into neurons. ScienceDaily. Retrieved January 5, 2019 from www.sciencedaily.com/releases/2018/11/181105122433.htm

Dr Carolyn Lam:                Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. I'm Dr Carolyn Lam, Associate Editor from the National Heart Center and Duke National University of Singapore.                                                 Our featured paper this week reports the five-year clinical outcomes and valve durability in the largest available cohort to date of consecutive high-risk patients undergoing transcatheter aortic valve replacement. You must listen up for this discussion, coming right up after these summaries.                                                 The first original paper describes a personalized risk assessment platform that promotes the implementation of precision medicine by helping us with the evaluation of a genomic variant of uncertain significance. A genomic variant of uncertain significance is a rare or novel variant for which disease pathogenicity has not been conclusively demonstrated or excluded and thus cannot be definitively annotated. These variants therefore pose critical challenges to the clinical interpretation and risk assessment. New methods are therefore urgently needed to better characterize their pathogenicity.                                                 Co-first authors, Dr Ma, Zhang, and Itzhaki, corresponding author Dr Wu from Stanford University School of Medicine and colleagues recruited a healthy, asymptomatic individual lacking cardiac disease clinical history and carrying hypertrophic cardiomyopathy associated genetic variant in the sarcomeric gene, MYL3, which has been reported by ClinVar database to be likely pathogenic.                                                 Human-induced pluripotent stem cells or IPSCs were derived from the heterozygous carrier, and their genome was edited using CRISPR/Cas9 genome editing to generate karyo-specific IPSCs. Extensive essays, including measurements of gene expression, sarcomere structure, cell size, contractility, action potentials, and calcium handling were performed on the isogenic IPSC-derived cardiomyocytes, and together, the platform was shown to elucidate both benign and pathogenic hypertrophic cardiomyopathy-functional phenotypes.                                                 Thus, this paper demonstrates for the first time the unique potential of combining IPSC-based disease modeling and CRISPR/Cas9 genome editing technology as a personalized risk assessment platform for determining the pathogenicity of a variant of unknown significance for hypertrophic cardiomyopathy in a patient-specific manner.                                                 Transcatheter aortic valve replacement is increasingly being used for the treatment of severe aortic valve stenosis in patients at intermediate risk for surgical aortic valve replacement. The next paper provides real world data comparing indications and clinical outcomes of patients at intermediate surgical risk undergoing isolated transcatheter vs. surgical aortic valve replacement.                                                 Co-first and corresponding others, Dr Werner and Zahn from Clinical Ludwigshafen in Germany compared clinical characteristics and outcomes of more than 7,600 patients with intermediate surgical risk who underwent isolated transcatheter or conventional surgical aortic valve replacement within the prospective all-comers, German aortic valve registry between 2012 and 2014.                                                 Multi-variable analyses reveal that factors that were associated with performing transcatheter instead of surgical aortic valve replacement included advanced age, coronary artery disease, New York Heart Association class three or four, pulmonary hypertension, prior cardiac decompensation, and elective procedure, arterial occlusive disease, no diabetes mellitus, and a smaller aortic valve area.                                                 Unadjusted in-hospital mortality rates were equal for transcatheter and surgical aortic valve replacement, whereas unadjusted one-year mortality was significantly higher in patients with transcatheter aortic valve replacement. After propensity score matching, the difference in one-year mortality was no longer significant. Thus, this large registry analysis suggests that both transcatheter and surgical aortic valve replacement are reasonable treatment options in a real world population with aortic stenosis and intermediate surgical risk.                                                 The next paper demonstrates a key role of vascular endothelial growth factor receptor 1 in hemorrhagic telangiectasia type 2. Now, this is an inherited genetic disorder where haplo-insufficiency of the activin receptor-like kinase 1 gene, ACVRL1, results in blood vessels that are prone to respond to angiogenic stimuli, leading to the development of telangiectatic lesions that can bleed.                                                 First author, Dr Thalgott, corresponding author, Dr Lebrin from Leiden University Medical Center and colleagues used ACVRL mutant mice and found that vascular endothelial growth factor, or VEGF receptor 1 levels were reduced, causing increased VEGF receptor 2 signaling that promoted sprouting angiogenesis, correcting the abnormal VEGF gradient, by expressing membranal-soluble VEGF receptor 1 in embryonic stem cells or blocking VEGF receptor 2 with antibodies in mutant mice, normalized the phenotype both in vitro and in vivo.                                                 Importantly, VEGF receptor 1 was reduced in the blood and skin blood vessels of patients with hemorrhagic telangiectasia type 2 compared with H match controls, demonstrating an important role of VEGF receptor 1 in these patients and explaining why their blood vessels might respond abnormally to angiogenic signals. These findings support the use of anti-VEGF therapy in hemorrhagic telangiectasia type 2.                                                 The next study suggests that hydroxychloroquine could be repurposed to reduce the risk of rheumatic heart disease following acute rheumatic fever. First author, Dr Kim, corresponding author, Dr Wicks from Walter and Eliza Hall Institute of Medical Research and University of Melbourne and their colleagues analyzed the immune response to group A streptococcus in peripheral blood mononuclear cells from an Australian Aboriginal acute rheumatic fever cohort by a combination of multiplex cytokine array, flow cytometric analysis, and global gene expression analysis by RNA sequencing.                                                 They then tested the widely used immunomodulatory drug, hydroxychloroquine for its effects on this response. They found that group A streptococcus activated persistent IL-1 beta production and selective expansion of a specific group of T helper 1 cells that produce GMCSF. Furthermore, hydroxychloroquine limited the expansion of these group A streptococcus-activated, GMCSF-producing T helper cells in vitro.                                                 Gene transcriptional profiling of peripheral blood mononuclear cells from patients with acute rheumatic fever showed dynamic changes at different stages of disease. Given the safety profile of hydroxychloroquine and its clinical pedigree in treating autoimmune diseases such as rheumatoid arthritis where GMCSF plays a pivotal role, the authors therefore proposed that hydroxychloroquine could be repurposed to reduce the risk of rheumatic heart fever following acute rheumatic fever.                                                 The next paper identifies a new anchoring B genetic variant in unrelated Han Chinese probands with ventricular tachycardia. In this paper from co-first authors, Dr Zhu, Wang and Hu, co-corresponding authors, Dr Hong from Second Affiliated Hospital of Nanjing University, Dr Mohler from Ohio State University Wexner Medical Center and colleagues, the authors identified the first anchoring B variant, Q1283H, localized to the ZU5C region in a proband with recurrent ventricular tachycardia.                                                 Knocking mice with this variant showed an increased susceptibility to arrhythmias associated with abnormal calcium dynamics. The variant was associated with loss of protein phosphatase 2A activity, increased phosphorylation of ryanodine receptor, exaggerated delayed after depolarization-mediated trigger activity, and arrhythmogenesis. Furthermore, the administration of metoprolol or flecainide decreased the incidence of stress-induced ventricular arrhythmias, representing potential therapies for anchoring B variant-associated arrhythmias.                                                 Does variability in metabolic parameters affect health outcomes? First author, Dr Kim, corresponding author, Dr Lee from Seoul Saint Mary's Hospital College of Medicine and Catholic University of Korea and their colleagues used nationally representative data from the Korean National Health Insurance system, consisting of more than 6.7 million people who are free of diabetes, hypertension, or dyslipidemia and who underwent three or more health examinations from 2005 to 2012 and were followed to the end of 2015.                                                 Variability and fasting blood glucose and total cholesterol, systolic blood pressure and body mass index was measured using the coefficient of variation, standard of deviation, variability independent of the mean, and average real variability. They found that a high variability in fasting glucose and cholesterol, systolic blood pressure and body mass index was associated with a higher risk for all-cause mortality, myocardial infarction, and stroke. Variabilities in several metabolic parameters had additive associations with the risk of mortality and cardiovascular outcomes in the general population.                                                 These findings suggest that treatment strategies to reduce fluctuations in metabolic parameters may be considered another goal to prevent adverse health outcomes.                                                 How much exercise over a lifetime is necessary to preserve efficient ventricular arterial coupling? First author Dr Hieda, corresponding author Dr Levine from Texas Health Presbyterian Hospital Dallas and University of Texas Southwestern Medical Center and colleagues studied 102 seniors and grouped them based on their 25 years of exercise training history. The dynamic Starling mechanism was estimated by transfer function gain between beat-by-beat changes in diastolic pulmonary artery pressure and stroke volume index.                                                 They found that there was a graded dose-dependent improvement in ventricular arterial coupling with increasing amounts of lifelong regular exercise in healthy older individuals. Their data suggested that the optimal does of lifelong endurance exercise to preserve ventricular arterial coupling with age appeared to be at least four to five sessions per week. The sufficient lifelong endurance exercise was effective for maintaining the normal dynamic Starling mechanism, left ventricular compliance, and arterial compliance with aging, all of which may lead to favorable effect on cardiovascular stiffness or function.                                                 And that brings us to the end of our summaries this week. Now, for our feature discussion.                                                 Transcatheter aortic valve replacement is taking over the interventional world. It's really rapidly growing, and we're increasingly using it for the treatment of aortic stenosis. It was initially used for inoperable and high-risk patients but now is indicated even in the treatment of intermediate-risk patient, and even low-risk patients are being enrolled into current trials.                                                 So, with TAVR being used for low- and intermediate-risk patients, the longer-term results of this treatment involved your abilities becoming more and more important. Well, gratefully, we have today's feature paper, and it describes the five-year clinical outcomes and valve durability of the FRANCE-2 Registry.                                                 I'm so pleased to have with us the corresponding author, Dr Martine Gilard from University Hospital of Brest in France, we have our editorialist, Dr Anita Asgar from Montreal Heart Institute, and we have our associate editor, Dr Dharam Kumbhani from UT Southwestern.                                                 Martine, congratulations on this largest cohort of high-risk patients and long-term outcomes. Could you please tell us what you found? Dr Martine Gilard:            Yes, and I'll just quote, actually, to have a follow-up of five years. We have 1,200 patients arrive at five years after rotation of TAVI. Each patient was a high-risk patient because it was at the beginning of each treatment, and in this time, it's only the high-risk patient was implanted with TAVI, and actually, we can follow this 1,200 patients, 50% of these patients of these patients have an echography because when we analyze these patients, we have an echography at five years, and the patients who have not echography at five years, the only difference is the age.                                                 It's very old patient. It's very difficult to make this echography on this patient to come back in our center, so it's why there is not all the patient who have an echography at five years.                                                 But our patients who have an echography, we can see that it's a very, very good result at five years. There is always the same area, just after before, of the valve. There is the same gradient. There is not a sign of deterioration.                                                 As you know, we have some guidelines published last year about how we asked to define deterioration of the valve, surgical or TAVI, and if we apply this new recommendation, we saw that in this largest cohort, at five years, there is only 13% of patient who have some sign of deterioration, and of these patients, we never need to make another valve in valve because the deterioration was not so important, and patient leave with this valve like that. There is no necessity to make a new valve in valve, so at five years of this very high-risk patient treated by TAVI, there is no necessity to implant a second valve because the valve deterioration. It's a very, very important message. Dr Carolyn Lam:                Thank you, Martine. Indeed, an important message. And Anita, you wrote a beautiful editorial about it. First, could I ask you to frame the issue? I mean, is there any reason we would expect the durability to be any different from a surgical replacement? Dr Anita Asgar:                  I think that's a great question, Carolyn, and I congratulate again Martine and her team for doing a fantastic job to add some very important results to the clinical literature on TAVI. Five years is relatively early to see structural valve deterioration, so in a sense, it's not surprising, and we would consider this sort of medium-term follow-up rather than really long-term durability, but very reassuring that in a high-risk population of patients, that TAVR performs very well in this population of patients and as mentioned, is very low to the dynamic structural valve deterioration.                                                 One question I have for Martine is, as you mentioned, there was only about 12% that had some evidence of structural valve deterioration hemodynamically, but this didn't result in another procedure, and I wonder if you could explain a little bit about that, whether it's the hemodynamic dynamic value, and yet there's a clinical indication for re-intervention. How do you incorporate the two? Dr Martine Gilard:            It's actually hemodynamic deterioration, there is some form of regurgitation. However, there is no need or clinical indication to make another intervention. So, if you compare this research to the bioprostheses surgical paths, the only one who have, at five years, no need to make a re-intervention appearing rotated, which is a valve, a surgical valve we have a longer bioprostheses surgical path.                                                 So, if we compare this best bioprostheses surgical valve, we have sustained results at five years. At five years, we have no need to make a re-intervention because the deterioration was not so important or as needed for clinical evidence as a need to make a new intervention. Dr Anita Asgar:                  So, there were some increased rates of heart failure in those patients with structural valve deterioration in your paper, and I know that in the paper you did mention that this is not an adjudicated outcome, and there wasn't a VARC definition for heart failure, but what's your interpretation of increasing heart failure events in these patients with structural valve deterioration? Dr Martine Gilard:            We have no real definition about that. We know that there is another registry. We say that there is an increasing of heart failure, and during the follow-up, and the result of this heart failure increase in mortality. There is an increasing of heart failure, but the number of these patients, there is more. So I don't know if this due to because patient is a high-risk patient, or it's because of the TAVI, but it's very difficult actually to have a real explanation about that. Dr Carolyn Lam:                Thanks, Anita and Martin. Dharam, could you share some of the thoughts and the discussions that were going on behind the scenes with the editors when we saw this paper? Dr Dharam Kumbhani:   Professor Gilard, this was a really excellent paper. We really appreciated you sending it to us, and I think for us, the fact that this was a very large cohort, the largest published cohort that has gotten to five years in a TAVR population, in a multicenter study, and having very good follow-up up to five years, with these patients is always this competing hazard that you want to know what the valve is doing at five years from an echocardiographic and hemodynamic perspective, but there's such a high competing hazard of death, just given the population that you're enrolling, and still, you had one of the largest echo follow-ups on these patients, so we want to congratulate you on the study and really a monumental endeavor, and so really great, great work there.                                                 And I think this is, exactly some of the questions that I think we had and I'm sure that the audience would have as well, I guess the one other question I have, and it's not really a question about your paper. So the median Euro score is 21 in this study, approximately 21, so that's obviously gonna, consistent with the patients that are being enrolled at that time between 2007 and 2012, which were predominantly high-risk and inoperable patients. Can you talk to us a little bit about the landscape of, how is TAVR practice in France as a society or from the regulatory standpoint, what are the benchmarks that you have achieve as you move towards low-risk now? Because intermediate-risk, I'm assuming is a [inaudible 00:20:16], so could you talk to us a little bit about the landscape there? Dr Martine Gilard:            Yes. In France, it's difficult because we have the authority to follow, not immediately, the ESC recommendations, so actually in France, we are allowed to implant only patients with high risk, patients with complication of surgery, and actually just since one year, patients with automatic risk, but we have no authorization to implant patient with low risk.                                                 However, the most important fact is the heart team, and if they write. Because we need to have something written, and if they write, if they explain that it's necessary to implant a patient at low risk because of some point while not including the risk score or it's very difficult to explain, for example, frailty or something, we can implant a patient with low risk.                                                 But normally actually, it is only for complication or high risk and for intermediate risk like the recommendation of the ESC.                                                 So the rate of implantation in France increased because we implant only 2,000 people per year, but actually, in 2017, we have implanted 10,200 patient, and this year, we think that we implant 12,800 patients, so as the number of patients increase, the number of patients who have a very high risk decrease because there is a futile indication, and we have a lot of futile indication, so we doesn't implant patient while too high-risk, and we select the most majority of patient implanted in France was high-risk but also intermediate-risk. Dr Dharam Kumbhani:   So, you think you're implanting more intermediate, like that is a bigger population that is getting TAVIs right now in France? Dr Martine Gilard:            Yes, exactly. Dr Carolyn Lam:                How about perspectives from Montreal? What do you think the implications of this findings from today's paper in relation to the types of patients that you might perform this in now? Dr Anita Asgar:                  For us, this is exceptionally reassuring, and as Martine has said, I mean, we have transitioned as well away from that very inoperable cohort C type of patient to more your higher-risk patient or intermediate, and to be honest, everyone over the age of 80 in Canada essentially is getting a TAVR. Dr Carolyn Lam:                Oh, wow. Dr Anita Asgar:                  Because regardless of their risk, and we've been very aggressive with that because trying to get patients back to an appropriate quality of life is very important, and to seeing this very reassuring data is telling us that, as she has already mentioned, we have reached the standard, at least in midterm follow-up as the gold standard of surgical valve replacement, and so structural valve deterioration is not as big a concern.                                                 I think we still however need longer-term data when we're looking at lower-risk patients, and lower-risk patients, let's remember, are not 60-year-olds. They're the 75-year-old, perhaps. But we're still gonna need some more data, but it's very reassuring, and patients are asking for it and are really advocating on their behalf to have a less invasive approach, and I think we can say now with more certainty that we know after five years, your chance of structural valve deterioration is actually quite low, and so I think that's very helpful from our point of view. Dr Carolyn Lam:                I love that, Anita, and it's so consistent with the title of your editorial, "Closing in on the Finish Line". Love it, love it, and recommend all listeners pick it up and have a good read. Dharam, I want to leave the last words to you. What do you think are the implications of this paper? Dr Dharam Kumbhani:   Well, I think that, as Anita said, this is very encouraging results that, in this kind of extreme and high-risk patient cohort, that there appear to be no medium- to long-term signals of structural valve degeneration, that the biggest hazard from this procedure is all upfront, and after that, it's pretty much, it's as we have seen with surgery, that after that, the actuarial rates come back to what you would expect.                                                 If they didn't have aortic stenosis and then they would die from whatever causes they had. Now obviously, that wasn't tested, but it seems like looking at the curves, that that seems like what's going on, so I think they've done a great service to our TAVR community in terms of showing us these results in very large, multicenter cohorts from France. Dr Carolyn Lam:                Thank you so much for joining us today. Thank you, listeners. You've been listening to Circulation on the Run. Don't forget to tune in again next week.                                                 This program is copyright American Heart Association, 2018.  

Hosts: Ed Brown, Penny Dumsday, Lucas Randall, Dr. Carolyn de Graaf 00:03:09 A large study has identified 35 genes that can influence you take up marijuana use. The study also also found links between those genes and other drug dependencies, as well as ADHD, autism and depression. 00:13:31 Scientists at Johns Hopkins Bloomberg School of Public Health has found that microorganisms in colder climates darken themselves to capture more heat and improve their chances for survival. 00:18:45 String Theory, the theoretical framework of cosmology, could permit trillions of trillions different universes. But one problem with it, according to a controversial new paper, is that it doesn't allow a universe like ours. 00:29:09 Archaeologists found a few broken jars in a 3,500 year old Egyptian tomb. Their contents were analysed, revealing an ancient love affair with one of life's true miracles: cheese.   Become a Patreon and help us out! Come see Dr. Pamela Gay and the Science on Top team in Melbourne on 10 October 2018! Get your tickets to the Australian Skeptics National Convention!   Dr Carolyn de Graaf is a geneticist from the Walter and Eliza Hall Institute.   This episode contains traces of Samoan Prime Minister Tuilaepa Sailele criticising climate change deniers.

Hosts: Ed Brown, Lucas Randall, Dr. Carolyn de Graaf 00:01:04 It was one of the most incredible news stories of the year - the rescue of twelve kids and their soccer coach from the flooded Thai cave. Made even more remarkable that they all returned in relatively good health - especially considering all the diseases and illnesses they were at risk of catching. 00:10:48 Whether it's Ebola, Hendra, SARS, or rabies; bats are often blamed for the spread of viruses. But is that fair? Are bats more likely to host diseases that spread to humans? 00:17:34 While hunting for Planet Nine, astronomers accidentally discovered 12 new moons around Jupiter. One of them is on a collision course! 00:28:54 Scientists Australia have developed a blood test which, in a recent trial, was successful in detecting melanomas in 81.5% of cases.   Carolyn de Graaf is a geneticist from the Walter and Eliza Hall Institute.   This episode contains traces of astronaut Scott Kelly describing the creepiest thing he encountered on the ISS.

David Glanz talks to Professor David Huang, 2018 Clunies Ross Knowledge Commercialisation Awardee, and collaborators Associate Professor Peter Czabotar and Associate Professor Guillaume Lessene. The three researchers, along with Professor Andrew Roberts, are recognised for their role in the development of a novel, potent anti-cancer drug called venetoclax. The drug, discovered in collaboration with Genentech, a member of the Roche Group, and AbbVie, was recently approved for use in the US, Europe and Australia to treat certain forms of chronic lymphocytic leukaemia (CLL). Derived from a basic research discovery in the late 1980s at the Walter and Eliza Hall Institute, the team’s findings helped to solve a problem that eluded international research efforts: inhibiting a family of pro-survival proteins called BCL-2. The solution involved expertise from each collaborator: Professor Huang led research unravelling the basic biology of the protein family; Associate Professors Lessene and Professor Czabotar focused on drug design and discovery; and Professor Roberts led translational and clinical research to establish its effectiveness in patients. They demonstrated that BCL-2 inhibitors had the potential to be exploited as an anti-cancer treatment. Pioneering clinical trials of venetoclax began in Australia in 2011 and saw outstanding results for patients. Some 79 per cent of people involved in two early phase clinical trials reported in 2016 had a promising result to the treatment. Both studies saw remissions in patients with advanced CLL for whom conventional treatment options had been exhausted. The social impacts of this drug will be enduring, benefiting patients and the health system and fuelling further investment and employment in the research sector – basic and translational. In July 2017, the Walter and Eliza Hall Institute of Medical Research completed a landmark deal, selling a part of its royalty rights in venetoclax for up to $US325 million. A portion of this income is being used to enhance and accelerate the discovery of new medicines, ensuring more cutting-edge medical research at the Walter and Eliza Hall Institute can be translated. The drug is now undergoing clinical trials to test its effectiveness in treating other types of cancer, with the hope it will benefit more patients in the future.

Joining Dr Shane In the studio this week is Dr Ray, Dr Krystal and Dr Linden. In news, plants and microbes can be friends; hookworms helping with diseases; and masers (microwave lasers). First guest is Dr Kate Sutherland and Dr Sarah Best, Stem Cells and Cancer Division, from the The Walter and Eliza Hall Institute of Medical Research. The discovery of a Cancer 'signature' by Melbourne researchers could be a step toward a blood test for patients with an aggressive and hard to treat type of lung cancer. The research revealed a unique molecular signature that could, in the future, be used to develop a simple blood test for these cancers. The next guest is Professor Leigh Ackland, Director of the Centre for Cellular & Molecular Biology at Deakin University. A world-first study of pregnant women has shown in humans for the first time that pregnancy can induce long-term epigenetic changes to our bodies, with major implications for understanding, preventing and treating disease. Deakin University scientists have discovered that pregnancy can cause long-term changes to the way women's genes behave, which could affect the future health of them and their children.

Cast: Danny, Akiel, and Grant Outro: Airplane Mode remix – Mega Ran Contact Us: unversedpodcast@gmail.com http://unversedpodcast.libsyn.com/ Follow Us: FB Tw IG: @UnversedPodcast Triple-Q: https://www.youtube.com/user/TripleKyun Marvel Talk: FB Tw IG: @MarvelTalkCast marveltalkpodcast@gmail.com https://facebook.com/MarvelTalkCast

In this week’s Success Story, Professor Gabrielle Belz, an award-winning scientist and Laboratory Head of the Molecular Immunology division at The Walter and Eliza Hall Institute of Medical Research (WEHI) explains to Catherine Robson the importance of nurturing a healthy gut, shares career advice for young scientists and her productivity hacks for managing the ‘reasonably unreasonable’ time demands of a career in science.

In the studio this week post radiothon are Dr Laura, Dr Krystal, Dr Ray and Dr Shane.News: Mosquito smartphone app.s from Oxford (humbug) and Standford Universities (abuzz); bacteriophages; the changes in light pollution and how climate change will change volcanic activity. The First guest (in the studio) is Romy Zyngier from The Department of Environment, Land, Water and Planning who talks about soil, biochar, soil libraries and The Homeward Bound program. The Second Guests (in the studio) is Dr Shalin Naik from The Walter and Eliza Hall Institute of Medical Research, who talks about the global HCA.(More) News: Thunderstorms and nuclear reactions; changing musical taste; and Brexit vs. Science funding.Remember, ""Science is everywhere"", including:Program page: http://www.rrr.org.au/program/einstein-a-go-go/ Facebook page: Einstein A Go Go Twitter: Einstein A Go Goand every Sunday at 11:00a.m AEST on RRR 102.7mHz FM.

Professor Jane Visvader is one of the world’s leading breast cancer researchers and joint head of stem cells and cancer research at the Walter and Eliza Hall Institute of Medical Research. She is at the forefront of giving women carrying the faulty BRCA1 gene, a precursor to breast cancer, preemptive treatment choices beyond the surgically invasive options of a mastectomy or oophorectomy (removal of the ovaries). Her impressive career spans various areas of science but a remarkable opportunity in 1998 led to her blazing the path of breast cancer treatment she’s on today. Speaking with Catherine Robson in this week’s Success Story, Jane talks about what it’s like to work alongside her husband, the scientific setbacks she’s faced, and her advice for young scientists.

Dr Melissa Davis is a computational biologist and  Laboratory Head of the Bioinformatics Division at the  Walter and Eliza Hall Institute. Driven by a passion to make the cancer diagnosis a less devastating one, Melissa and her team are at the cutting edge of bioinformatic studies aimed to reduce the traumatic side effects patients experience while being treated for cancer. In this week's Success Story, Melissa shares with Catherine Robson the role sophisticated data analytics and mathematical modelling play in revolutionising cancer treatment and why a difficult financial decision led to the career she loves today.

Helping one city understand the realities of food insecurity. In This Podcast: Finishing her master's degree required a semester project and Cindy Tran's had fallen through since the city food policy she was going to evaluate had not been passed yet. Realizing the city leaders either did not fully understand what food security was or how significant the issue of food insecurity was for their own citizens, she developed a new project to fix this.  Cindy spent her semester gathering all the evidence, including what city already commissioned, and helped frame it in a report that convinced them there was an issue and that it could be tackled. This helped the city take action and the resulting food system strategy is one worth emulating in many other cities. Don't miss an episode! Click here to sign up for weekly podcast updatesor visit www.urbanfarm.org/podcast Cindy completed a Bachelor of Biomedicine degree at the University of Melbourne with a major in Pathology and matured her quantitative research skills at the Walter and Eliza Hall Institute as a research student.  She subsequently completed her Masters of Public Health at the University of Melbourne.  Cindy specialized in health policy & promotion, and developed a good understanding of the Australian Health Care System.  She has a strong interest in obesity and diabetes and how these are influenced by our cities and food system.  Cindy produced a background report collating local evidence about the issue of food security within the City of Moreland.  This report contributed to the endorsement of the Moreland Food System Strategy in May 2017. Go to www.urbanfarm.org/moreland for more information and links on this podcast, and to find our other great guests.

Dr Shane, Dr Linden, Dr Lauren and Dr Catherine bring you this week's hottest science, including Victoria's driest June on record, new research into safe levels of air pollution, Japan's moonshot, defensive behaviour in different coloured fairy wrens, delivering the flu vaccine via a band-aid, and petunias' fragrance.The team talk to Peter Scales, Director of Engagement at the Melbourne School of Engineering, about the Victorian Indigenous Engineering Winter School, and also about his work with water recycling programs around the world.They also interview Professor Benjamin Solomon from the Department of Medical Oncology at the Peter MacCallum Cancer Centre and also Dr Clare Weeden from the Walter and Eliza Hall Institute for Medical Research, about their work with different types of lung cancer.Program page: http://www.rrr.org.au/program/einstein-a-go-go/ Facebook page: Einstein A Go Go Twitter: https://twitter.com/einstein_agogoand every Sunday at 11:00a.m AEST on RRR 102.7FM.

In the studio this week are Dr. Linden, Dr. Lauren II, Dr. Ray and Dr Shane.News: Cowherd Mathematics, Global risk of deadly heatwave events, The shape of eggs, Coronal mass solar ejections and thanks to listener Guy on the discussion around the use of CO2 capture discussion.The First guest (in the studio) is Professor Brian Smith, Head of the School of Molecular Sciences, Latrobe University who talks about molecular modelling.The Second Guest (in the studio) is Saskia Freytag, Researcher at Walter and Eliza Hall Institute of Medical Research who talks about how she started in mathematics and her research analysing big data relating to gene expression in the post-mortem brain. http://choosemaths.org.au/More News: Comparing modern blue-green algae with 100 year old blue-green algae and the origin of deadly viruses (to humans).Remember, ""Science is everywhere"", including:Program page: http://www.rrr.org.au/program/einstein-a-go-go/ Facebook page: Einstein A Go Go Twitter: https://twitter.com/einstein_agogoand every Sunday at 11:00a.m AEST on RRR 102.7mHz FM.

In the studio this week are Dr Lauren, Dr Catherine and Dr Shane. The First guest (in the studio) is Lucy Weaver from CSIRO talking about how smart polymers are used for cleaning up salty wastewater and famelab. The Second Guests (in the studio) are Professor David Huang and Dr Mary Ann Anderson from Walter and Eliza Hall Institute of Medical Research talk about their history and their group's discovery of a groundbreaking drug for leukaemia treatment. News: Zika virus, active Vitamin D and childhood asthma. Remember, ""Science is everywhere"", including: Program page: http://www.rrr.org.au/program/einstein-a-go-go/ Facebook page: Einstein A Go Go Twitter: https://twitter.com/einstein_agogo and every Sunday at 11:00a.m AEST on RRR 102.7mHz FM.

Dr Shane, Dr Lauren, Dr Ailie and Dr Ray bring you the week's hot science, including concrete absorbing carbon dioxide, climate change links to storms that produce multiple tornadoes, printable temporary tattoos to measure sun exposure, and confirmation of new elements.They speak to Professor Michael Bell, Chair in Tropical Agronomy, School of Agriculture and Food Sciences, about the upcoming International Nitrogen Initiative conference and problems with the use of nitrogen in agriculture.They interview Professor Sue Heinzel, Ph.D. President, Australasian Society for Immunology, and Dr. Lynn Corcoran from the Immunology Division, Walter and Eliza Hall Institute for Medical Research, about their discovery that two internal 'clocks' control the immune cells enlisted to fight infection. This discovery, published today in Nature Immunology, upends previous theories on how immune responses are regulated.Finally, they chat with Rebecca Mitchell, Land Management Extension Officer with the Department of Economic Development, Jobs, Transport and Resources in the Government of Victoria, about World Soil Day.Program page: http://www.rrr.org.au/program/einstein-a-go-go/ Facebook page: Einstein A Go Go Twitter: https://twitter.com/einstein_agogo

Dr Shane, Dr Lauren and Dr Ray bring you another hour of the week's hottest science, including rats that use tools and other animals that display interesting intelligent behaviour, remote monitoring of plankton blooms, the crash of the ESA Schiaparelli Mars probe, and earthquake propagation being dissipated by magma. Dr Shane also reviews Longitude by Dava Sobel.The team speak with Associate Professor Mike Lawrence, from the Walter and Eliza Hall Institute of Medical Research, who is working in the area of how Insulin works and a how a venom from a marine cone snail could help to develop ultra-fast-acting insulin, leading to more effective therapies for diabetes management.They also chat with Professor Paul Webley, the director of the Peter Cook Centre for Carbon Capture and Storage Research, and the CO2CRC Capture Program Manager, from the Department of Chemical and Biomolecular Engineering at the University of Melbourne, about the new carbon storage research facility that was recently launched.Program page: http://www.rrr.org.au/program/einstein-a-go-go/ Facebook page: Einstein A Go Go Twitter: https://twitter.com/einstein_agogo

Dr Shane is joined in the studio with fellow Einstein A Go Go team members Dr Chromo, Dr Krystal and Dr Ailie.The team kick the show off with science news.Dr Chromo talks nature under threat, then shares recent studies into whether the immune system could be controlling your behaviour. Dr Krystal shares recent (accidental) developments with Graphene, a material stronger than steel and as hard as diamond. Dr Ailie then delves into the world of dinosaurs and alternative extinction theories. Dr Shane then explains we have a new dwarf planet in our midst.First Guest: Dr Alisa Barry - Walter and Eliza Hall Institute.Dr Alisa joins the team in the studio to discuss different types of Malaria and more specifically one particular strain which isn't often talked about.Second Guest : Ms. Nadia Bellofiore - Hudson Research Institute.Nadia joins in the team in the studio to discuss the somtimes rarely spoken about topic of menstruation. More specifically menstruation in mice, answering the age old question, 'Do mice get periods?'Dr Krystal then leads a discussion with the team on the ever developing area of genes and asks the question; Can you change your genes?Remember, Science is everywhere, Including :Program page: http://www.rrr.org.au/program/einstein-a-go-go/ Facebook page: Einstein A Go Go Twitter: https://twitter.com/einstein_agogo

Dr Shane, Dr Ailie and Dr Krystal discuss this week's hot science stories, including storing carbon dioxide in volcanic rock, a global atlas of light pollution, and the Juno spacecraft's pending arrival at Jupiter.The team talk to Jennifer Walz from the Florey Institute, about her group's research, involving a new method of analysing brainwave data to determine the sequence that different brain regions are activated during a patient's seizure, which can be used to customise treatments for each patient.They also interview Jane Visvader from the Walter and Eliza Hall Institute, whose research team's studies have revealed that breast cells develop two nuclei as the breast switches on lactation to nurture the newborn.Finally, that talk with Professor Elizabeth Hartland, the Head of the Department of Microbiology and Immunology at the University of Melbourne, and Deputy Director, Peter Doherty Institute for Infection and Immunity. Her team believe they have found a major response that helps keep the Legionella infection at bay. With this discovery, they have dissected the complex roles of legions of immune cells that interact to destroy the bacterium. This would enable patients to have a more accurate prognosis for the infection, giving vital information about when to use antibiotics.Program page: http://www.rrr.org.au/program/einstein-a-go-go/ Facebook page: Einstein A Go Go Twitter: https://twitter.com/einstein_agogo

Dr Shane, Dr Ray and Emily (Zoos Victoria guest) discuss spider mating habits, weed killer links to cancer, a crazy plan to probe the Jupiter moon Europa and Zoos Victoria 'Don't Palm Us Off Project'.Second Guest: Bernard Wood, Professor of Human Origins and Director of the Center for the Advanced Study of Human Paleobiology, George Washington University tells us all about his extensive research into paleoanthropology.Third Guest: Travis Park, School of Biological Sciences, Monash University discusses his current research which includes the earliest members of the two living groups of whales.Fourth Guest: Dr Julia Marchingo,PhD graduate and receiver of the Victorian Young Achiever Award, Walter and Eliza Hall Institute of Medical Research tells us all about her groundbreaking immunology research as well as her advocacy for vaccination and gender equity.Program page: http://www.rrr.org.au/program/einstein-a-go-go/ Facebook page: Einstein A Go Go Twitter: https://twitter.com/einstein_agogo

Dr Shane is joined by Dr Ray and Dr Krystal. First guest is Drew Barry who is a Bafta and Emmy-award-winning Drew Berry has been a biomedical animator at the Walter and Eliza Hall Institute for 20 years. Drew's animations bring to life biological processes that are difficult for people to comprehend and impossible to observe. Drew was awarded the MacArthur fellowship AKA 'Genius Grant' to pursue his work in science communication. This fellowship has recently come to a close and Drew is reflecting on all that it has enabled him to achieve. Guest 2 Professor Andrew Tonkin from Monash University Cardiovascular disease is still the number one killer in Australia, despite ongoing efforts in prevention and treatment. A major national Monash University collaboration is now testing whether a safe, one-off vaccination can help to reduce the risk of heart attacks and strokes. Guest 3 is Georgia Atkin-Smith, PhD Candidate from the La Trobe Institute for Molecular Science at La Trobe University Georgia's research focuses on the understanding how white blood cells die. This research project combines novel cell biological techniques with immunological assays to understand the implications of cell death within our immune system.

Everything gets a little more sciencey in National Science Week, on from 16-23 August. We do a round-up of some of the top events around the country, and take a look at this year's theme for the International Year of Light.We also talk to lung cancer researcher Kate Sutherland about Science in the Square, celebrating 100 years of the Walter and Eliza Hall Institute of Medical Research (WEHI) and ask: will there ever be a cure for cancer?

Sir Gustav Nossal arrived in Australia from Vienna when he was eight years old. He graduated from Sydney University’s Medical School with first class honours and gained his PhD degree in 1960. Sir Gustav is one of Australia’s most celebrated scientists. His research accomplishments are world-renowned, with his work confirming Burnet’s theory of antibody formation a watershed in understanding of the immune system. As researcher and director of The Walter and Eliza Hall Institute of Medical Research from 1965 to 96, he helped build the foundations of modern immunology and define the field for more than 30 years. Sir Gustav has been directly involved with the World Health Organization since 1967, most recently as chairman of the Global Programme for Vaccines and Immunization, and has helped shape the scientific affairs of Australia for decades. As president of the Australian Academy of Science he provided valuable input to government policy-making, and has been an influential public commentator on scientific and medical issues. His many lectures and radio and television appearances have inspired ongoing popular and political interest in science and its applications. Sir Gustav is chairman of the Strategic Advisory Council for the Bill and Melinda Gates Children’s Vaccine Program, which works to ensure children in developing countries are immunized. He is also deputy chairman of the Council for Aboriginal Reconciliation and deputy chairman of the Advisory Council of The Global Foundation. He is also heavily involved in charitable work and is patron of a number of organisations. The Nossal Institute for Global Health at the University of Melbourne and the Nossal High School at Monash University are named in his honour. He is a fellow of the Royal Society of London, a foreign associate of the US National Academy of Sciences and a member of the Académie des Sciences, France.  

EAGG 19th April 2015Hosts: Dr Krystal, Dr, Kathryn, Dr Jen, Dr ShaneNews items: The possible origins of antibacterial resistance, How does the skeletal muscles respond to a high fat diet?, New research in the placebo effect, Earthquake warning from mobile phones.First guest: Chiara Paviolo, PhD. The most common treatments for cancer are surgery or a combination of chemotherapy and radiotherapy. Recently, gold nanoparticles have been employed in cancer cell therapy under laser illumination or as drug delivery systems. We showed that gold nanorods can also inhibit cell proliferation through a mechanical blocking of receptor clustering. Membrane receptors are proteins that provide the first line of communication between the extracellular environment and the cell cytoplasm.Second guest: Dr Natalie Thorne is a statistician, and mother to three young children. She had an early interest in genetics during her Bachelor of Science degree in the late 90's. She worked with Professor Terry Speed, a world renowned bioinformatician and statistician, when she was in second year university. She went on to complete her Honours and PhD work in bioinformatics at the Walter and Eliza Hall Institute with Terry.Third guest:Professor Jo Douglas, Head of the Department of Immunology and Allergy, Royal Melbourne Hospital. Jo Douglass is a specialist physician who is Head of the Department of Immunology and Allergy at the Royal Melbourne Hospital, an Honorary Clinical Professor at the University of Melbourne and Research Associate at the Walter & Eliza Hall Institute. She undertook medical training at Monash University and specialist physician training in Allergy and Respiratory Medicine in Australia and the UK, receiving her MD in 2000 with a thesis based on bench-top immunology and continues to contribute to publications and clinical research. She is a Fellow of the Thoracic Society of Australia and New Zealand and a former President of the Australasian Society of Clinical Immunology and Allergy (ASCIA). Her current research projects are in severe asthma, allergies and immune deficiencies. She also maintains an active clinical practice. http://www.dayofimmunology.org.au/Home/Remember, "Science is everywhere", including:http://www.rrr.org.au/program/einstein-a-go-go/http://rrrfm.libsyn.com/category/Einstein%20A%20Go%20Goand every Sunday at 11a.m AEST on RRR 102.7mHz FM

At our 150th episode celebration earlier this year, we were fortunate to have Dr. Krystal Evans address the audience to talk about science in Australia. Dr. Evans is a medical researcher at the Walter and Eliza Hall Institute where she is working on Malaria treatment and developing a vaccine. She is a leading advocate for science and technology, and was a founding member and Chair of the Australian Academy of Science's Early and Mid Career Researcher Forum. In this talk she looks at how Australia stacks up against the rest of the world - both in scientific accomplishments and in investment. She talks about ways to motivate scientists to engage with the public, and also how to encourage the public to take an interest in science. And she answers that burning question: just how much is Australian politics like going on a date with a homeopath?

In today’s episode, I talk to Matthew Witkowski, a PhD student at the Walter and Eliza Hall Institute in Melbourne, on his research into the relationship between the Ikaros Gene and Leukemia. We discuss: – Matt’s background – A definition of leukaemia – Matt’s work in his PhD – What is the Ikaros gene? – […]

Professor Michael Good is a NHMRC Australia Fellow at Griffith University, the past Director of the Queensland Institute of Medical Research, a past President of the Association of Australian Medical Research Institutes, and a past Director of the Cooperative Research Centre for Vaccine Technology. In 2006 he was appointed as Chair of the National Health and Medical Research Council of Australia. In 2008 he was a Steering Committee member and Co-Chair of the "long-term national health strategy" of the 2020 Summit. Also in 2008 he was awarded an Officer of the Order of Australia (AO) for service to medical research and contributions to education. In 2009 he won the Australian Museum CSIRO Eureka Prize for Leadership in Science. In 2010 he was named a "Queensland Great" by the Queensland Premier. He graduated MD PhD DSc from the University of Queensland and the Walter and Eliza Hall Institute of Medical Research in Melbourne. His interests are in the field of immunity and immunopathogenesis to malaria and group A streptococcus/rheumatic fever, with particular relevance to the development of vaccines. In the spirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TEDTalks video and live speakers combine to spark deep discussion and connection in a small group. These local, self-organized events are branded TEDx, where x = independently organized TED event. The TED Conference provides general guidance for the TEDx program, but individual TEDx events are

Hosts: Ed Brown, Penny Dumsday, Dr. Krystal Evans. Topics covered: Dr. Krystal gives us an in-depth progress report on malaria treatment - is this the year we start winning the war on malaria? Also Penny tells us how nematode worms can distinguish good bacteria from harmful bacteria, and the discovery of two sunken 'mini-continents' off the coast of West Australia. Plus an update on the troubled Phobos-Grunt probe - it's alive! And more results for those faster-than-light neutrinos. Dr. Krystal is a malaria researcher at the Walter and Eliza Hall Institute.

0:00:00IntroductionRichard Saunders0:06:50Maynard's Spooky Action....Interview with Laughter Strategies' Helene Groverhttp://laughterstrategies.com 0:24:28Dr Rachie ReportsInterview with PhD researcher Lina Happo from the Walter and Eliza Hall Institute about her work into cell death and cancer.http://www.wehi.edu.au0:33:00Dr Rachie on the Radio Hear her tear a piece out of homeopathy!

Emma Josefsson bedriver uppmärksammad forskning vid Walter and Eliza Hall Institute i Melbourne. Genom att studera blodplättar kan man få en mängd svar om vårt blod och hur blodplättar uppträder kring en cancer cell. - Emma Josefsson bedriver uppmärksammad forskning vid Walter and Eliza Hall Institute i Melbourne. Genom att studera blodplättar kan man få en mängd svar om vårt blod och hur blodplättar uppträder kring en cancer cell.